1 |
**comment**- imp inhalation solution identical to ventavis inhalation solution, but imp is in a different volume presentation. please see covering letter. |
- |
- |
- |
- |
086 1件: 86 💬 |
2 |
0.9% normal saline (control) |
- |
- |
- |
- |
299 1件: 299 💬 |
3 |
0.9% sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 4件: 6 , 14, 51, 53 💬 |
4 |
0.9% sodium chloride (normal saline) |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 1件: 6 💬 |
5 |
0.9% sodium chloride injection |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
168 1件: 168 💬 |
6 |
0.9% w/v isotonic sodium chloride solution |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
050 1件: 50 💬 |
7 |
0.9% w/v sodium chloride solution |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
299 1件: 299 💬 |
8 |
100 mg elx/50 mg tez/75 mg iva fixed dose combination |
- |
- |
- |
- |
299 1件: 299 💬 |
9 |
13 valent conjugated pneumococcal vaccine |
- |
- |
- |
- |
265 1件: 265 💬 |
10 |
13-valent pneumococcal conjugate vaccine |
- |
- |
- |
- |
046 2件: 46, 53 💬 |
11 |
13-valent pneumococcal conjugate vaccine (13-pcv) |
- |
- |
- |
- |
013 1件: 13 💬 |
12 |
13-valent pneumococcal conjugated vaccine (pcv13) |
- |
- |
- |
- |
096 1件: 96 💬 |
13 |
15 o water |
Water |
1件: D00001 D00001 💬 |
- |
- |
019 1件: 19 💬 |
14 |
15-o labeled water |
Water |
1件: D00001 D00001 💬 |
- |
- |
046 1件: 46 💬 |
15 |
150 mg double-blinded secukinumab |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
16 |
150 mg open-label secukinumab |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
17 |
20mg/0.5ml glatiramer acetate |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
18 |
3-hydroxy-2-methyl-4h-pyrane-4-one iron (iii) complex (3:1), ferric (3-hydroxy-2-methyl-4-pyrone), tris-maltol-iron (iii), tri=maltol-iron (iii) |
Tromethamine |
1件: D00396 D00396 💬 |
- |
- |
096 2件: 96, 97 💬 |
19 |
300 mg double-blinded secukinumab |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
20 |
40 mg glatiramer acetate |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
002 2件: 2 , 13 💬 |
21 |
40 mg glatiramer acetato |
Glatiramer |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
22 |
5 asa, enemas, suppositories, corticosteroids |
- |
- |
- |
- |
097 1件: 97 💬 |
23 |
5% glucose water solution |
Dextrose, unspecified form |
1件: D00001 D00001 💬 |
- |
- |
002 1件: 2 💬 |
24 |
5% lidocaine/5 mg/ml 0.02% estradiol compound cream |
Estradiol |
11件: D00105 D00105, D00358 D00358, D01413 D01413, D01617 D01617, D01953 D01953, D02086 D02086, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065, D08127 D08127 💬 |
ESR1 7件: ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 12件: Adrenergic signaling in cardiomyocytes, Breast cancer, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway |
226 1件: 226 💬 |
25 |
5-probe cocktail |
- |
- |
- |
- |
254 1件: 254 💬 |
26 |
50 mg elx/25 mg tez/37.5 mg iva fixed dose combination |
- |
- |
- |
- |
299 1件: 299 💬 |
27 |
5000 iu of cholecalciferol |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
299 1件: 299 💬 |
28 |
7-valent pneumococcal conjugate vaccine |
- |
- |
- |
- |
046 1件: 46 💬 |
29 |
90 mg hydrocortisone acetate suppository with sephure suppository applicator |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
30 |
A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine |
Clarithromycin |
3件: D00276 D00276, D00278 D00278, D00424 D00424 💬 |
- |
- |
096 1件: 96 💬 |
31 |
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (cbus) |
- |
- |
- |
- |
060 1件: 60 💬 |
32 |
A natural remedy for rheumatoid arthritis vs. common drugs |
- |
- |
- |
- |
046 1件: 46 💬 |
33 |
A-glucosidasi acida umana ricombinante coniugata con multiple copie di bis-mannosio-6- fosfato-tetra-mannosio glicano sintetico (neogaa) |
Avalglucosidase alfa |
1件: D11744 D11744 💬 |
GAA 1件: GAA 💬 |
Galactose metabolism 4件: Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
256 1件: 256 💬 |
34 |
Aav9-cag-coh-sgsh |
- |
- |
- |
- |
019 1件: 19 💬 |
35 |
Aavrh.10cuhcln2 vector 2.85x10^11 genome copies |
- |
- |
- |
- |
019 1件: 19 💬 |
36 |
Aavrh.10cuhcln2 vector 9.0x10^11 genome copies |
- |
- |
- |
- |
019 1件: 19 💬 |
37 |
Ace-031 (extension of cohort 1 from core study, a031-03) |
- |
- |
- |
- |
113 1件: 113 💬 |
38 |
Ace-031 (extension of cohort 2 from core study, a031-03) |
- |
- |
- |
- |
113 1件: 113 💬 |
39 |
Ace-031 (extension of cohort 3 from core study, a031-03) |
- |
- |
- |
- |
113 1件: 113 💬 |
40 |
Acei/arb and corticosteroids |
- |
- |
- |
- |
066 1件: 66 💬 |
41 |
Acomplia 20 mg film-coated tablets |
- |
- |
- |
- |
193 1件: 193 💬 |
42 |
Active comparator |
- |
- |
- |
- |
006 2件: 6 , 46 💬 |
43 |
Active comparator receiving extavia® |
- |
- |
- |
- |
013 1件: 13 💬 |
44 |
Active control |
- |
- |
- |
- |
013 1件: 13 💬 |
45 |
Actonel 5mg film coated tablets |
- |
- |
- |
- |
274 1件: 274 💬 |
46 |
Actonel once a week 35 mg film-coated tablets |
- |
- |
- |
- |
274 1件: 274 💬 |
47 |
Actonel once a week 5mg film coated tablets |
- |
- |
- |
- |
113 1件: 113 💬 |
48 |
Actonel/optinate 5mg film-coated tablets |
- |
- |
- |
- |
274 1件: 274 💬 |
49 |
Ada umbilical cord blood cells |
- |
- |
- |
- |
065 1件: 65 💬 |
50 |
Adcirca 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
51 |
Adempas - 0,5 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
086 1件: 86 💬 |
52 |
Adempas - 1 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
53 |
Adempas - 1,5 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
54 |
Adempas - 2 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
55 |
Adempas - 2,5 mg - compressa rivestita con film - uso orale - blister (pp/alu) - 42 compresse |
- |
- |
- |
- |
051 2件: 51, 86 💬 |
56 |
Adempas 0.5 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
57 |
Adempas 1 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
58 |
Adempas 1.5 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
59 |
Adempas 2 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
60 |
Adempas 2.5 mg film coated tablet |
- |
- |
- |
- |
086 1件: 86 💬 |
61 |
Adempas® 0.5 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
62 |
Adempas® 1.0 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
63 |
Adempas® 1.5 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
64 |
Adempas® 2.0 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
65 |
Adempas® 2.5 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
66 |
Adempas¿ 0.5 mg compressa rivestita con film |
- |
- |
- |
- |
086 1件: 86 💬 |
67 |
Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene |
- |
- |
- |
- |
113 1件: 113 💬 |
68 |
Adeno-associated viral vector serotype 9 containing the human n-acetyl-alpha-glucosaminidase gene |
- |
- |
- |
- |
019 1件: 19 💬 |
69 |
Adipose-cord mesenchymal stromal cells (a-mscs) |
Human Umbilical Cord Mesenchymal Stem Cells |
- |
- |
- |
097 1件: 97 💬 |
70 |
Adjuvant without active component |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
71 |
Adrenal cortical hormone |
- |
- |
- |
- |
224 1件: 224 💬 |
72 |
Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994 |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
046 1件: 46 💬 |
73 |
Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994) |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
046 1件: 46 💬 |
74 |
Alkalinized lidocaine-heparin |
Heparin |
4件: D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A 6件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes 4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
75 |
Allogeneic human umbilical cord tissue-derived mesenchymal stem cells |
- |
- |
- |
- |
013 1件: 13 💬 |
76 |
Allogeneic mesenchymal stromal cells derived from the umbilical cord |
Human Umbilical Cord Mesenchymal Stem Cells |
- |
- |
- |
049 1件: 49 💬 |
77 |
Ambrisentan 5 mg film-coated tablets |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
78 |
Ambrisentan 5mg film-coated tablets [marketed product] |
Ambrisentan |
1件: D07077 D07077 💬 |
EDNRA 1件: EDNRA 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
79 |
Amiodarone |
Amiodarone |
2件: D00636 D00636, D02910 D02910 💬 |
ADRA1A 16件: ADRA1A, ADRA1B, ADRA1D, ADRB1, KCND3, KCNJ11, KCNJ12, KCNJ3, KCNJ5, KCNJ8, KCNQ1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
AMPK signaling pathway 31件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Dilated cardiomyopathy, Dopaminergic synapse, Estrogen signaling pathway, Gap junction, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, Insulin secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Pancreatic secretion, Protein digestion and absorption, Regulation of lipolysis in adipocytes, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Type II diabetes mellitus, Vascular smooth muscle contraction, Vibrio cholerae infection, cAMP signaling pathway, cGMP-PKG signaling pathway |
028 2件: 28, 127 💬 |
80 |
Amitriptyline, fluoxetine and tramadol alone (control group) |
Amitriptyline |
6件: D00326 D00326, D00809 D00809, D00823 D00823, D01355 D01355, D07448 D07448, D08623 D08623 💬 |
OPRM1 3件: OPRM1, SLC6A2, SLC6A4 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
078 1件: 78 💬 |
81 |
Ammonium chloride |
Ammonium chloride |
1件: D01139 D01139 💬 |
- |
- |
096 1件: 96 💬 |
82 |
Androgel 10 grams of gel containing 100 mg of testosterone |
Testosterone |
6件: D00075 D00075, D00957 D00957, D00958 D00958, D00959 D00959, D06085 D06085, D06087 D06087 💬 |
AR 1件: AR 💬 |
Oocyte meiosis 3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
013 1件: 13 💬 |
83 |
Angiotensin-converting enzyme (ace) inhibitor |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
224 1件: 224 💬 |
84 |
Angiotensin-converting enzyme inhibitor(acei) |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
224 1件: 224 💬 |
85 |
Anti human granulocyte-macrophage colo |
- |
- |
- |
- |
046 1件: 46 💬 |
86 |
Anti human granulocyte-macrophage colony-stimulating factor (gm-csf) monoclonal |
- |
- |
- |
- |
046 1件: 46 💬 |
87 |
Anti human granulocyte-macrophage colony-stimulating factor (gm-csf) monoclonal antibody |
- |
- |
- |
- |
046 1件: 46 💬 |
88 |
Anti tnf humanized antibody fab fragment-peg conjugate |
- |
- |
- |
- |
096 1件: 96 💬 |
89 |
Anti-tnf humanized antibody fab fragment - peg conjugate |
- |
- |
- |
- |
046 1件: 46 💬 |
90 |
Anti-tnf humanized antibody fab' fragment - peg conjugate |
- |
- |
- |
- |
046 1件: 46 💬 |
91 |
Anti-tnfa continued perioperatively |
- |
- |
- |
- |
046 1件: 46 💬 |
92 |
Antibiotic cocktail |
- |
- |
- |
- |
097 1件: 97 💬 |
93 |
Antimicrobial therapy: co-trimoxazole or doxycycline |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
085 1件: 85 💬 |
94 |
Antioxidant cocktail |
- |
- |
- |
- |
299 1件: 299 💬 |
95 |
Arcoxia 90 mg comprimidos recubiertos con película |
- |
- |
- |
- |
271 1件: 271 💬 |
96 |
Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis) |
Atazanavir |
3件: D00427 D00427, D01276 D01276, D07471 D07471 💬 |
- |
- |
265 1件: 265 💬 |
97 |
Atg conditioning regimen |
- |
- |
- |
- |
060 1件: 60 💬 |
98 |
Aubagio - 14 mg - compressa rivestita con film - uso orale - blister (alu/alu) - 28 compresse |
- |
- |
- |
- |
013 1件: 13 💬 |
99 |
Autologous (self) mononuclear cells derived from umbilical cord blood |
- |
- |
- |
- |
211 1件: 211 💬 |
100 |
Autologous cd34+ cells transduced with a lentiviral vector containing the human sgsh gene |
- |
- |
- |
- |
019 1件: 19 💬 |
101 |
Autologous cd34+ cells transduced with the lentiviral vector containing the human wiskott aldrich sy |
- |
- |
- |
- |
065 1件: 65 💬 |
102 |
Autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with lentiviral vector that encodes for the human wiskott aldrich syndrome (was) cdna sequence |
- |
- |
- |
- |
065 1件: 65 💬 |
103 |
Autologous human placental cord blood mononuclear cells |
- |
- |
- |
- |
211 1件: 211 💬 |
104 |
Autologous umbilical cord blood |
- |
- |
- |
- |
211 2件: 211, 294 💬 |
105 |
Avalox - 400 mg compresse rivestite con film 5 compresse in blister pp/al |
- |
- |
- |
- |
006 1件: 6 💬 |
106 |
Avonex/betaseron/copaxone/rebif |
- |
- |
- |
- |
013 1件: 13 💬 |
107 |
Azd4017 and prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
075 1件: 75 💬 |
108 |
Azilect 1 mg comprimidos |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
109 |
Azithromycin + n-acetylcystein + inhaled corticosteroid |
Azithromycin |
3件: D02134 D02134, D06390 D06390, D07486 D07486 💬 |
- |
- |
228 1件: 228 💬 |
110 |
Azithromycin 500 mg film-coated tablet |
Azithromycin |
3件: D02134 D02134, D06390 D06390, D07486 D07486 💬 |
- |
- |
299 1件: 299 💬 |
111 |
B-peptide-crm197 conjugate |
- |
- |
- |
- |
011 1件: 11 💬 |
112 |
Balsalazide |
Balsalazide |
2件: D02715 D02715, D07488 D07488 💬 |
- |
- |
097 1件: 97 💬 |
113 |
Balsalazide disodium |
Balsalazide |
2件: D02715 D02715, D07488 D07488 💬 |
- |
- |
097 1件: 97 💬 |
114 |
Bay 63-2521 coated tablets 0.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
115 |
Bay 63-2521 coated tablets 1 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
116 |
Bay 63-2521 coated tablets 1.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
117 |
Bay 63-2521 coated tablets 2 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
118 |
Bay 63-2521 coated tablets 2.5 mg |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
119 |
Bay 63-2521 ir coated tablet 1.0 mg |
- |
- |
- |
- |
088 1件: 88 💬 |
120 |
Bay 63-2521 ir coated tablet 1.5 mg |
- |
- |
- |
- |
088 1件: 88 💬 |
121 |
Bay 63-2521 ir coated tablet 2.0 mg |
- |
- |
- |
- |
088 1件: 88 💬 |
122 |
Bay 63-2521 ir coated tablet 2.5 mg |
- |
- |
- |
- |
088 1件: 88 💬 |
123 |
Befizal l.p. 400 mg, comprimé enrobé à libération prolongée |
- |
- |
- |
- |
094 1件: 94 💬 |
124 |
Behavioral: adherence counseling |
- |
- |
- |
- |
013 1件: 13 💬 |
125 |
Behavioral: assessment of cognition |
- |
- |
- |
- |
006 1件: 6 💬 |
126 |
Behavioral: assessment of impact of ms on cognition |
- |
- |
- |
- |
013 1件: 13 💬 |
127 |
Behavioral: assessment of severity of icd (impulse control disorders) |
- |
- |
- |
- |
006 1件: 6 💬 |
128 |
Behavioral: attention control |
- |
- |
- |
- |
006 1件: 6 💬 |
129 |
Behavioral: co-op treatment protocol |
- |
- |
- |
- |
006 1件: 6 💬 |
130 |
Behavioral: cognitive and behavioral experimental tasks |
- |
- |
- |
- |
006 2件: 6 , 127 💬 |
131 |
Behavioral: collaborative care (cc) |
- |
- |
- |
- |
013 1件: 13 💬 |
132 |
Behavioral: colonic lavage |
- |
- |
- |
- |
291 1件: 291 💬 |
133 |
Behavioral: combined balance and brisk walking training |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
134 |
Behavioral: conservative measures for orthostatic hypotension |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
135 |
Behavioral: conservative treatment |
- |
- |
- |
- |
291 1件: 291 💬 |
136 |
Behavioral: diet and water adjustment |
Water |
1件: D00001 D00001 💬 |
- |
- |
067 1件: 67 💬 |
137 |
Behavioral: diet counseling |
- |
- |
- |
- |
096 1件: 96 💬 |
138 |
Behavioral: dietary counseling |
- |
- |
- |
- |
046 1件: 46 💬 |
139 |
Behavioral: healthy age-matched controls |
- |
- |
- |
- |
006 1件: 6 💬 |
140 |
Behavioral: increased dietary intake of salmon or cod |
Salmon, unspecified |
- |
- |
- |
097 1件: 97 💬 |
141 |
Behavioral: low-impact exercise control |
- |
- |
- |
- |
006 1件: 6 💬 |
142 |
Behavioral: montreal cognitive assessment (moca) |
- |
- |
- |
- |
017 1件: 17 💬 |
143 |
Behavioral: protein and calorie controlled diet |
- |
- |
- |
- |
251 1件: 251 💬 |
144 |
Behavioral: respiratory and exercise therapy with supplemental oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
088 1件: 88 💬 |
145 |
Behavioral: telephone-based cognitive behavioral therapy |
- |
- |
- |
- |
013 1件: 13 💬 |
146 |
Behavioral: tip / impact plus care coordination |
- |
- |
- |
- |
046 3件: 46, 96, 97 💬 |
147 |
Behavioral: water tracking |
Water |
1件: D00001 D00001 💬 |
- |
- |
013 1件: 13 💬 |
148 |
Benlysta - 120 mg - polvere per concentrato per soluzione per infusione - uso endovenoso - flaconcino (vetro) 120 mg 1 flaconcino |
- |
- |
- |
- |
053 1件: 53 💬 |
149 |
Benlysta 400 mg powder for concentrate for solution for infusion |
- |
- |
- |
- |
043 2件: 43, 49 💬 |
150 |
Benlysta 400 mg powder for concentrate for solution for infusions |
- |
- |
- |
- |
049 1件: 49 💬 |
151 |
Benlysta 400mg polvere per concentrato per soluzione per infusione |
- |
- |
- |
- |
043 1件: 43 💬 |
152 |
Berberine |
Berberine |
1件: D00092 D00092 💬 |
- |
- |
097 1件: 97 💬 |
153 |
Berberine chloride |
Berberine |
1件: D00092 D00092 💬 |
- |
- |
097 1件: 97 💬 |
154 |
Beta-adrenergic cocktail |
- |
- |
- |
- |
299 1件: 299 💬 |
155 |
Biib033 (anti-lingo) - ev substance code sub118957 |
- |
- |
- |
- |
013 1件: 13 💬 |
156 |
Bio-enhanced curcumin soft gelatin capsule |
Curcumin |
2件: D00115 D00115, D06892 D06892 💬 |
- |
- |
097 1件: 97 💬 |
157 |
Biological: umbilical cord based allogenic mesenchymal stem cell |
- |
- |
- |
- |
113 1件: 113 💬 |
158 |
Bladder instillation with heparin/ lidocaine |
Heparin |
4件: D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A 6件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes 4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
159 |
Blokium 50 mg comprimidos |
- |
- |
- |
- |
167 1件: 167 💬 |
160 |
Blood coagulation factor viii and vwf, human |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
161 |
Blood coagulation factor xiii |
Factor XIII (human) |
- |
- |
- |
051 1件: 51 💬 |
162 |
Blood collection |
- |
- |
- |
- |
271 1件: 271 💬 |
163 |
Blood sample collection |
- |
- |
- |
- |
085 1件: 85 💬 |
164 |
Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin) |
Digoxin |
13件: D00298 D00298, D00330 D00330, D00455 D00455, D00529 D00529, D00550 D00550, D00696 D00696, D01207 D01207, D01475 D01475, D02290 D02290, D05028 D05028, D05259 D05259, D05261 D05261, D08229 D08229 💬 |
ATP1A1 25件: ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP4A, ATP4B, CYSLTR1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, PTGS1, PTGS2 💬 |
Adrenergic signaling in cardiomyocytes 49件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Arachidonic acid metabolism, Bile secretion, C-type lectin receptor signaling pathway, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Chemical carcinogenesis, Collecting duct acid secretion, Endocrine and other factor-regulated calcium reabsorption, GABAergic synapse, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Insulin secretion, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Nicotine addiction, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pancreatic secretion, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, Taste transduction, Thyroid hormone signaling pathway, Thyroid hormone synthesis, VEGF signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 1件: 46 💬 |
165 |
Bone marrow concentrate |
- |
- |
- |
- |
070 1件: 70 💬 |
166 |
Boots high strength garlic odour controlled |
Garlic |
- |
- |
- |
299 1件: 299 💬 |
167 |
Botulinum toxin a - haemagglutinin complex |
Botulinum toxin type A |
1件: D00783 D00783 💬 |
SNAP25 1件: SNAP25 💬 |
Insulin secretion 2件: Insulin secretion, Synaptic vesicle cycle |
013 1件: 13 💬 |
168 |
Bovine type i collagen |
Bovine type I collagen |
- |
- |
- |
051 1件: 51 💬 |
169 |
Bpr277 ointment (controlled application) |
- |
- |
- |
- |
160 1件: 160 💬 |
170 |
Bupivacaine/epinephrine/dexamethasone |
Bupivacaine |
14件: D00095 D00095, D00292 D00292, D00975 D00975, D00996 D00996, D01450 D01450, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02149 D02149, D02174 D02174, D02591 D02591, D02592 D02592, D07552 D07552 💬 |
ADRA1A 15件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, NR3C1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
AMPK signaling pathway 15件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
096 1件: 96 💬 |
171 |
Busilvex - 6 mg/ml - concentrato per soluzione per infusione - uso endovenoso - flaconcino - 10 ml 8 flaconcini |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
172 |
Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen) |
Antithymocyte immunoglobulin (rabbit) |
5件: D00248 D00248, D00287 D00287, D01907 D01907, D07760 D07760, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
326 1件: 326 💬 |
173 |
C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker |
Polyethylene glycol |
1件: D03370 D03370 💬 |
- |
- |
276 1件: 276 💬 |
174 |
C1 inhibitor concentrate |
Human C1-esterase inhibitor |
- |
- |
- |
065 1件: 65 💬 |
175 |
Cabozantinib |
Cabozantinib |
1件: D10062 D10062 💬 |
AXL 3件: AXL, KDR, MET 💬 |
Adherens junction 24件: Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Epithelial cell signaling in Helicobacter pylori infection, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, Hepatocellular carcinoma, MAPK signaling pathway, Malaria, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Renal cell carcinoma, Transcriptional misregulation in cancer, VEGF signaling pathway |
034 1件: 34 💬 |
176 |
Calcium and cholecalciferol |
Calcium |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
046 1件: 46 💬 |
177 |
Calcium and vitamin d combination |
Calcium |
- |
- |
- |
013 1件: 13 💬 |
178 |
Canakinumab (company code: acz885d) |
Canakinumab |
1件: D09315 D09315 💬 |
IL1B 1件: IL1B 💬 |
AGE-RAGE signaling pathway in diabetic complications 42件: AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
106 1件: 106 💬 |
179 |
Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
180 |
Carbidopa, levodopa, entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
181 |
Carbidopa/l-dopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
182 |
Carbidopa/levodopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
183 |
Carvedilol |
Carvedilol |
2件: D00255 D00255, D03415 D03415 💬 |
ADRA1A 5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 💬 |
AMPK signaling pathway 12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 5件: 6 , 57, 86, 113, 210 💬 |
184 |
Cbdv compound |
Cannabidivarin |
- |
- |
- |
193 1件: 193 💬 |
185 |
Cellcept 500 mg comprimidos recubiertos |
- |
- |
- |
- |
035 1件: 35 💬 |
186 |
Cellcept 500 mg film-coated tablets |
- |
- |
- |
- |
011 1件: 11 💬 |
187 |
Cellcept®500 mg comprimidos |
- |
- |
- |
- |
035 1件: 35 💬 |
188 |
Cellule cd34+ autologhe trasdotte con idua lv codificante per il cdna dell'alfa-l-iduronidasi |
- |
- |
- |
- |
019 1件: 19 💬 |
189 |
Cfz533 active - cohort 1 |
- |
- |
- |
- |
053 1件: 53 💬 |
190 |
Cfz533 active - cohort 2 |
- |
- |
- |
- |
053 1件: 53 💬 |
191 |
Cfz533 active - cohort 3 |
- |
- |
- |
- |
053 1件: 53 💬 |
192 |
Cfz533 active -cohort 3 |
- |
- |
- |
- |
053 1件: 53 💬 |
193 |
Chemical conjugate of recombinant human growth hormone (rhgh) and human immunoglobulin g4 fragment (hmc001) |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
194 |
Chicken type ii collagen |
Chicken |
- |
- |
- |
046 1件: 46 💬 |
195 |
Chinese herbal concoction twice a day for 6 months |
- |
- |
- |
- |
060 1件: 60 💬 |
196 |
Chlorpromazine |
Chlorpromazine |
4件: D00270 D00270, D00789 D00789, D03274 D03274, D04034 D04034 💬 |
ADRA2A 13件: ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2B, HTR2C 💬 |
Alcoholism 22件: Alcoholism, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Cocaine addiction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Regulation of actin cytoskeleton, Salivary secretion, Serotonergic synapse, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway |
254 1件: 254 💬 |
197 |
Chlorpromazine hydrochloride |
Chlorpromazine |
4件: D00270 D00270, D00789 D00789, D03274 D03274, D04034 D04034 💬 |
ADRA2A 13件: ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2B, HTR2C 💬 |
Alcoholism 22件: Alcoholism, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Cocaine addiction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Regulation of actin cytoskeleton, Salivary secretion, Serotonergic synapse, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway |
254 1件: 254 💬 |
198 |
Cholecalciferol |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 💬 |
199 |
Cholecalciferol (vitamin d3) |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 2件: 13, 299 💬 |
200 |
Cholecalciferol (vitamind3) |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
299 1件: 299 💬 |
201 |
Cholecalciferol 10,000 iu |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
096 1件: 96 💬 |
202 |
Cholecalciferol 400 iu |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
096 1件: 96 💬 |
203 |
Cholecalciferol and c. xanthorrhiza |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
049 1件: 49 💬 |
204 |
Cholecalciferol concentrate |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
096 1件: 96 💬 |
205 |
Cholecalciferol concentrate (water-dispersible form) |
Cholecalciferol |
2件: D00001 D00001, D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
096 1件: 96 💬 |
206 |
Cholecalciferol, vitamin d3 |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 1件: 13 💬 |
207 |
Chronic corticosteroid therapy |
- |
- |
- |
- |
113 1件: 113 💬 |
208 |
Cialis - 20 mg 2 compresse rivestite con film in blister uso orale |
- |
- |
- |
- |
075 1件: 75 💬 |
209 |
Cialis 10 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
210 |
Cialis 2.5 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
211 |
Cialis 20 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
212 |
Cialis 20 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
213 |
Cialis 5 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
214 |
Circadin 2 mg comprimidos de liberación prolongada |
- |
- |
- |
- |
090 1件: 90 💬 |
215 |
Claritromycin 500mg film coated tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
216 |
Clenbuterol |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
001 4件: 1 , 2 , 6 , 256 💬 |
217 |
Clenbuterol hcl |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
218 |
Clenbuterol hydrochloride |
Clenbuterol |
1件: D07713 D07713 💬 |
ADRB2 1件: ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
219 |
Clobetasol propionate |
Clobetasol |
2件: D01272 D01272, D07715 D07715 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 2件: 46, 162 💬 |
220 |
Clobetasol propionate + methotrexate |
Clobetasol |
4件: D00142 D00142, D01272 D01272, D02115 D02115, D07715 D07715 💬 |
DHFR 3件: DHFR, DHFR2, NR3C1 💬 |
Antifolate resistance 6件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, Neuroactive ligand-receptor interaction, One carbon pool by folate |
162 1件: 162 💬 |
221 |
Clobetasol propionate alone |
Clobetasol |
2件: D01272 D01272, D07715 D07715 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
162 1件: 162 💬 |
222 |
Clobetasol propionate cream treatment |
Clobetasol |
2件: D01272 D01272, D07715 D07715 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
162 1件: 162 💬 |
223 |
Co |
- |
- |
- |
- |
006 5件: 6 , 13, 53, 70, 85 💬 |
224 |
Co-14 |
- |
- |
- |
- |
013 1件: 13 💬 |
225 |
Co-medication: synthetic dmards |
- |
- |
- |
- |
046 1件: 46 💬 |
226 |
Co-trimoxazole |
- |
- |
- |
- |
085 1件: 85 💬 |
227 |
Coa |
- |
- |
- |
- |
120 1件: 120 💬 |
228 |
Coagulación factor viii |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
229 |
Coagulation factor viii |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
230 |
Coagulation factor xiii |
Factor XIII (human) |
- |
- |
- |
288 1件: 288 💬 |
231 |
Coamoxiclav |
- |
- |
- |
- |
097 1件: 97 💬 |
232 |
Cobalt |
Cobalt |
- |
- |
- |
046 1件: 46 💬 |
233 |
Cobamamide |
Cobamamide |
1件: D00042 D00042 💬 |
- |
- |
299 1件: 299 💬 |
234 |
Cobiprostone |
Cobiprostone |
1件: D08893 D08893 💬 |
- |
- |
046 1件: 46 💬 |
235 |
Cobitolimod |
Cobitolimod |
- |
- |
- |
097 1件: 97 💬 |
236 |
Cocoa |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
237 |
Coconut |
Coconut |
- |
- |
- |
013 2件: 13, 53 💬 |
238 |
Coconut oil |
Coconut |
1件: D05326 D05326 💬 |
- |
- |
013 1件: 13 💬 |
239 |
Coconut oil and epigallocatechin gallate |
Coconut |
1件: D05326 D05326 💬 |
- |
- |
013 1件: 13 💬 |
240 |
Cod |
- |
- |
- |
- |
046 1件: 46 💬 |
241 |
Cod liver oil |
Cod liver oil |
1件: D03578 D03578 💬 |
- |
- |
046 1件: 46 💬 |
242 |
Coenzym q10 nanodispersion |
- |
- |
- |
- |
005 1件: 5 💬 |
243 |
Coenzym q10, ubiquinon, ubichinon |
- |
- |
- |
- |
005 1件: 5 💬 |
244 |
Coenzyme q |
- |
- |
- |
- |
013 1件: 13 💬 |
245 |
Coenzyme q-10 |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
086 1件: 86 💬 |
246 |
Coenzyme q-10 in normal control subjects |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
086 1件: 86 💬 |
247 |
Coenzyme q-10 in pulmonary hypertension subjects |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
086 1件: 86 💬 |
248 |
Coenzyme q10 |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
002 12件: 2 , 5 , 6 , 8 , 10, 18, 46, 57, 113, 193, 214, 215 💬 |
249 |
Coenzyme q10 and lisinopril |
Lisinopril |
3件: D00362 D00362, D01065 D01065, D08131 D08131 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
113 1件: 113 💬 |
250 |
Coenzyme q10 nanodispersion (nanoquinone) |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
006 1件: 6 💬 |
251 |
Coenzyme q10 with vitamin e |
Ubidecarenone |
2件: D01065 D01065, D02331 D02331 💬 |
- |
- |
006 1件: 6 💬 |
252 |
Coenzymeq10 |
- |
- |
- |
- |
021 1件: 21 💬 |
253 |
Cofactor |
- |
- |
- |
- |
006 3件: 6 , 265, 288 💬 |
254 |
Cofactor supplementation (thiamine, riboflavin, l-carnitine) |
Levocarnitine |
7件: D00050 D00050, D01622 D01622, D01913 D01913, D02030 D02030, D02176 D02176, D04713 D04713, D08580 D08580 💬 |
- |
- |
265 1件: 265 💬 |
255 |
Coffee |
- |
- |
- |
- |
096 2件: 96, 97 💬 |
256 |
Coffee coal |
- |
- |
- |
- |
097 1件: 97 💬 |
257 |
Cogane |
- |
- |
- |
- |
006 1件: 6 💬 |
258 |
Cogane™ (pym50028) |
- |
- |
- |
- |
006 1件: 6 💬 |
259 |
Cohort 1 0.225g |
- |
- |
- |
- |
240 1件: 240 💬 |
260 |
Cohort 1: 1.0 x 10^8 polytregs |
- |
- |
- |
- |
035 1件: 35 💬 |
261 |
Cohort 1: hatg, csa, epag day 14 to month 6 |
Antilymphocyte immunoglobulin (horse) |
1件: D08808 D08808 💬 |
- |
- |
060 1件: 60 💬 |
262 |
Cohort 1:nilotinib oral capsules (150mg or 300mg) |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
263 |
Cohort 2 0.75g |
- |
- |
- |
- |
240 1件: 240 💬 |
264 |
Cohort 2: 2.5x10^8 polytregs |
- |
- |
- |
- |
035 1件: 35 💬 |
265 |
Cohort 2: hatg, csa, epag day 14 to month 3 |
Antilymphocyte immunoglobulin (horse) |
1件: D08808 D08808 💬 |
- |
- |
060 1件: 60 💬 |
266 |
Cohort 2: nilotinib oral capsules (dose to be determined from cohort 1) |
Nilotinib |
1件: D08953 D08953 💬 |
ABL1 4件: ABL1, KIT, PDGFRA, PDGFRB 💬 |
Acute myeloid leukemia 32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis |
006 1件: 6 💬 |
267 |
Cohort 3 2.25 g |
- |
- |
- |
- |
240 1件: 240 💬 |
268 |
Cohort 3: hatg, csa (dose reduced), epag day 1 to month 6 |
Antilymphocyte immunoglobulin (horse) |
1件: D08808 D08808 💬 |
- |
- |
060 1件: 60 💬 |
269 |
Col7a1-sin retroviral vector engineered autologous tissue-engineered skin |
- |
- |
- |
- |
036 1件: 36 💬 |
270 |
Colal pred |
- |
- |
- |
- |
097 1件: 97 💬 |
271 |
Colal-pred |
- |
- |
- |
- |
097 1件: 97 💬 |
272 |
Colal-pred® |
- |
- |
- |
- |
097 1件: 97 💬 |
273 |
Colazide |
- |
- |
- |
- |
097 1件: 97 💬 |
274 |
Colchicina |
Colchicine |
1件: D00570 D00570 💬 |
TUBB 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 |
Alzheimer disease 10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection |
002 1件: 2 💬 |
275 |
Colchicina lirca - 1 mg compresse 60 compresse |
Colchicine |
1件: D00570 D00570 💬 |
TUBB 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 |
Alzheimer disease 10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection |
002 1件: 2 💬 |
276 |
Colchicine |
Colchicine |
1件: D00570 D00570 💬 |
TUBB 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 |
Alzheimer disease 10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection |
002 7件: 2 , 42, 46, 56, 93, 210, 266 💬 |
277 |
Colchicine 1 mg oral tablet |
Colchicine |
1件: D00570 D00570 💬 |
TUBB 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 |
Alzheimer disease 10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection |
002 1件: 2 💬 |
278 |
Colchicine sprinkle capsules |
Colchicine |
1件: D00570 D00570 💬 |
TUBB 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 |
Alzheimer disease 10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection |
266 1件: 266 💬 |
279 |
Colecalciferol |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 4件: 13, 46, 96, 228 💬 |
280 |
Colecalciferol concentrate (oily form) |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 1件: 13 💬 |
281 |
Colecalciferol d3 (vigantol oil) |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
096 1件: 96 💬 |
282 |
Colesevelam |
Colesevelam |
2件: D03582 D03582, D07743 D07743 💬 |
- |
- |
096 2件: 96, 260 💬 |
283 |
Colestipol |
Colestipol |
2件: D02113 D02113, D07771 D07771 💬 |
- |
- |
254 1件: 254 💬 |
284 |
Colestyramine |
Cholestyramine |
- |
- |
- |
254 1件: 254 💬 |
285 |
Colimicina |
- |
- |
- |
- |
299 1件: 299 💬 |
286 |
Colimicina - 1000000 u/4 ml polvere e solvente per soluzione iniettabile per uso intramuscolare1 flaconcino polvere + 1 fiala solvente 4 ml |
- |
- |
- |
- |
299 1件: 299 💬 |
287 |
Colimycine |
- |
- |
- |
- |
299 1件: 299 💬 |
288 |
Colimycine inhalation |
- |
- |
- |
- |
299 1件: 299 💬 |
289 |
Colimycine injectable |
- |
- |
- |
- |
299 1件: 299 💬 |
290 |
Colistimetato sodico |
- |
- |
- |
- |
299 1件: 299 💬 |
291 |
Colistimethat-natrium |
- |
- |
- |
- |
299 1件: 299 💬 |
292 |
Colistimethate |
Colistimethate |
1件: D02049 D02049 💬 |
- |
- |
299 1件: 299 💬 |
293 |
Colistimethate 75 mg inhaled two times daily |
Colistimethate |
1件: D02049 D02049 💬 |
- |
- |
299 1件: 299 💬 |
294 |
Colistimethate sodium |
Colistimethate |
1件: D02049 D02049 💬 |
- |
- |
299 1件: 299 💬 |
295 |
Colistimethate sodium (a component) |
Colistimethate |
1件: D02049 D02049 💬 |
- |
- |
299 1件: 299 💬 |
296 |
Colistimethate sodium (ban, usan), colistimethatum natricum, colistin sodium methanesulfonate |
Colistimethate |
3件: D02049 D02049, D02138 D02138, D07746 D07746 💬 |
- |
- |
299 1件: 299 💬 |
297 |
Colistimethate sodium (promixin) |
Colistimethate |
1件: D02049 D02049 💬 |
- |
- |
299 1件: 299 💬 |
298 |
Colistin |
Colistin |
2件: D02138 D02138, D07746 D07746 💬 |
- |
- |
299 1件: 299 💬 |
299 |
Colistin cf |
Colistin |
2件: D02138 D02138, D07746 D07746 💬 |
- |
- |
299 1件: 299 💬 |
300 |
Colistin forest - trockenstechampullen mit lösungsmittel |
Colistin |
2件: D02138 D02138, D07746 D07746 💬 |
- |
- |
299 1件: 299 💬 |
301 |
Colistin mesilate sodium |
Colistin |
2件: D02138 D02138, D07746 D07746 💬 |
- |
- |
299 1件: 299 💬 |
302 |
Colistineb |
- |
- |
- |
- |
299 1件: 299 💬 |
303 |
Colistineb 2mui |
- |
- |
- |
- |
299 1件: 299 💬 |
304 |
Collagenase |
Collagenase clostridium histolyticum |
1件: D09596 D09596 💬 |
- |
- |
162 1件: 162 💬 |
305 |
Collect of 10 ml of peripheric blood for dna extraction |
- |
- |
- |
- |
046 1件: 46 💬 |
306 |
Collection of blood and urine |
- |
- |
- |
- |
025 1件: 25 💬 |
307 |
Colobreathe |
- |
- |
- |
- |
299 1件: 299 💬 |
308 |
Colomycin |
- |
- |
- |
- |
299 1件: 299 💬 |
309 |
Colony-purified bacteroides thetaiotaomicron (b.theta) |
- |
- |
- |
- |
096 1件: 96 💬 |
310 |
Coltect |
- |
- |
- |
- |
097 1件: 97 💬 |
311 |
Combination |
- |
- |
- |
- |
046 1件: 46 💬 |
312 |
Combination antiviral therapy |
- |
- |
- |
- |
093 1件: 93 💬 |
313 |
Combination fish oil and borage seed oil |
Fish oil |
- |
- |
- |
046 1件: 46 💬 |
314 |
Combination injection of epo and g-csf |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
006 1件: 6 💬 |
315 |
Combination of a single dose anti-cd20 antibody and bortezomib |
Bortezomib |
1件: D03150 D03150 💬 |
PSMB5 1件: PSMB5 💬 |
Alzheimer disease 8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
061 1件: 61 💬 |
316 |
Combination of fish oil and colesevelam |
Colesevelam |
2件: D03582 D03582, D07743 D07743 💬 |
- |
- |
260 1件: 260 💬 |
317 |
Combination of minocycline and mtx or mtx alone |
Minocycline |
2件: D00850 D00850, D05045 D05045 💬 |
- |
- |
046 1件: 46 💬 |
318 |
Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine |
Azathioprine |
12件: D00238 D00238, D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592, D02994 D02994, D03033 D03033 💬 |
MS4A1 2件: MS4A1, NR3C1 💬 |
Hematopoietic cell lineage 2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction |
035 1件: 35 💬 |
319 |
Combination of thrombopoietin mimetic and cyclosporin a |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
060 1件: 60 💬 |
320 |
Combination oral budesonide and rectal hydrocortisone |
Budesonide |
2件: D00088 D00088, D00246 D00246 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
321 |
Combination product (natpara) and drug or supplements [disease and drug registry] |
- |
- |
- |
- |
235 1件: 235 💬 |
322 |
Combination product: device: axially oscillating sphere dry powder inhaler (aos dpi) |
- |
- |
- |
- |
086 1件: 86 💬 |
323 |
Combination product: active treatment with dual therapy |
- |
- |
- |
- |
002 1件: 2 💬 |
324 |
Combination product: beclomethasone dipropionate in addition to mc-evoo |
Beclomethasone dipropionate |
2件: D00689 D00689, D07495 D07495 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
325 |
Combination product: beclomethasone dipropionate in addition to refined oil |
Beclomethasone dipropionate |
2件: D00689 D00689, D07495 D07495 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
326 |
Combination product: belimumab |
Belimumab |
1件: D03068 D03068 💬 |
TNFSF13B 1件: TNFSF13B 💬 |
Cytokine-cytokine receptor interaction 4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
049 1件: 49 💬 |
327 |
Combination product: goldic serum |
- |
- |
- |
- |
070 1件: 70 💬 |
328 |
Combination product: hyperbaric oxygen therapy- |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
226 1件: 226 💬 |
329 |
Combination product: implantable system for remodulin (treprostinil) |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
330 |
Combination product: l-dopa 140 mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
331 |
Combination product: l-dopa 35 mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
332 |
Combination product: l-dopa 70mg |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
333 |
Combination product: l-dopa 70mg/carbidopa 7mg |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
334 |
Combination product: mavrilimumab |
Mavrilimumab |
1件: D09930 D09930 💬 |
CSF2RA 1件: CSF2RA 💬 |
Cytokine-cytokine receptor interaction 4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
041 1件: 41 💬 |
335 |
Combination product: methotrexate |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
336 |
Combination product: nd0612 solution for sc infusion |
- |
- |
- |
- |
006 1件: 6 💬 |
337 |
Combination product: ofatumumab with ai |
Ofatumumab |
1件: D09314 D09314 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
013 1件: 13 💬 |
338 |
Combination product: ofatumumab with prf |
Ofatumumab |
1件: D09314 D09314 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
013 1件: 13 💬 |
339 |
Combination product: prp combined magnovision |
- |
- |
- |
- |
090 1件: 90 💬 |
340 |
Combination product: transcon pth |
- |
- |
- |
- |
235 1件: 235 💬 |
341 |
Combination product: treprostinil via implanted pump |
Treprostinil |
1件: D06213 D06213 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
342 |
Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
343 |
Combination steroid |
- |
- |
- |
- |
046 1件: 46 💬 |
344 |
Combination therapy with vigabatrin and prednisolone |
Prednisolone |
9件: D00472 D00472, D00535 D00535, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
ABAT 2件: ABAT, NR3C1 💬 |
Alanine, aspartate and glutamate metabolism 8件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism |
145 1件: 145 💬 |
345 |
Combined plasma exchange (pex), rituximab, and corticosteroids |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
085 1件: 85 💬 |
346 |
Combivir |
- |
- |
- |
- |
265 1件: 265 💬 |
347 |
Combivir (zidovudine [azt] / lamivudine [3tc]) |
Lamivudine |
2件: D00353 D00353, D00413 D00413 💬 |
- |
- |
265 1件: 265 💬 |
348 |
Commercial formulation etanercept |
Etanercept |
1件: D00742 D00742 💬 |
LTA 2件: LTA, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
349 |
Commercial ventavis® (iloprost) |
Iloprost |
1件: D02721 D02721 💬 |
PTGIR 1件: PTGIR 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
086 1件: 86 💬 |
350 |
Common name: sialic acid |
- |
- |
- |
- |
030 1件: 30 💬 |
351 |
Comparator: carbidopa |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
352 |
Comparator: diclofenac |
Diclofenac |
3件: D00903 D00903, D00904 D00904, D07816 D07816 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 1件: 46 💬 |
353 |
Comparator: diclofenac sodium |
Diclofenac |
3件: D00903 D00903, D00904 D00904, D07816 D07816 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 1件: 46 💬 |
354 |
Comparator: ezetimibe |
Ezetimibe |
1件: D01966 D01966 💬 |
NPC1L1 1件: NPC1L1 💬 |
Fat digestion and absorption 1件: Fat digestion and absorption |
079 2件: 79, 260 💬 |
355 |
Comparator: levodopa |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
356 |
Comparator: naproxen tablet 500 mg |
Naproxen |
1件: D00118 D00118 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 1件: 46 💬 |
357 |
Complement c1 esterase inhibitor |
Conestat alfa |
1件: D10845 D10845 💬 |
C1R 3件: C1R, C1S, KLKB1 💬 |
Complement and coagulation cascades 6件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Pertussis, Phagosome, Staphylococcus aureus infection, Systemic lupus erythematosus |
061 1件: 61 💬 |
358 |
Compound 1a |
- |
- |
- |
- |
246 2件: 246, 299 💬 |
359 |
Compound 21 |
- |
- |
- |
- |
085 1件: 85 💬 |
360 |
Compound thrombosis capsule sig: 1.5g/tid |
- |
- |
- |
- |
090 1件: 90 💬 |
361 |
Comtan |
- |
- |
- |
- |
006 1件: 6 💬 |
362 |
Comtan 200* 60 cpr 200 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
363 |
Comtan® |
- |
- |
- |
- |
006 1件: 6 💬 |
364 |
Comtanâ® |
- |
- |
- |
- |
006 1件: 6 💬 |
365 |
Comtess |
- |
- |
- |
- |
006 1件: 6 💬 |
366 |
Comtess® |
- |
- |
- |
- |
006 1件: 6 💬 |
367 |
Concentration unit: mg milligram(s) |
- |
- |
- |
- |
254 1件: 254 💬 |
368 |
Concerta |
- |
- |
- |
- |
203 1件: 203 💬 |
369 |
Conditioned medium (cm) |
- |
- |
- |
- |
090 1件: 90 💬 |
370 |
Confortid |
- |
- |
- |
- |
225 1件: 225 💬 |
371 |
Conivaptan |
Conivaptan |
2件: D01236 D01236, D07748 D07748 💬 |
AVPR1A 2件: AVPR1A, AVPR2 💬 |
Calcium signaling pathway 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption |
086 1件: 86 💬 |
372 |
Conjugated equine estrogens |
Conjugated estrogens |
2件: D04070 D04070, D05987 D05987 💬 |
- |
- |
049 1件: 49 💬 |
373 |
Conjugated equine estrogens 0.625 mg/d + mpa 5 mg/d/10d |
Conjugated estrogens |
2件: D04070 D04070, D05987 D05987 💬 |
- |
- |
049 1件: 49 💬 |
374 |
Continuation of azathioprine |
Azathioprine |
2件: D00238 D00238, D03033 D03033 💬 |
- |
- |
049 1件: 49 💬 |
375 |
Continuation of current haart (boosted protease inhibitor [pi] combination + 2 nrtis) |
- |
- |
- |
- |
265 1件: 265 💬 |
376 |
Continuous apomorphine infusion |
Apomorphine |
2件: D02004 D02004, D07460 D07460 💬 |
DRD1 2件: DRD1, DRD2 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
377 |
Continuous infusion cefepime |
Cefepime |
1件: D02376 D02376 💬 |
- |
- |
299 1件: 299 💬 |
378 |
Continuous infusion ceftazidime |
Ceftazidime |
2件: D00921 D00921, D07654 D07654 💬 |
- |
- |
299 1件: 299 💬 |
379 |
Continuous infusion meropenem |
Meropenem |
2件: D02222 D02222, D08185 D08185 💬 |
- |
- |
299 1件: 299 💬 |
380 |
Continuous infusion piperacillin tazobactam |
Piperacillin |
4件: D00466 D00466, D00660 D00660, D02251 D02251, D08380 D08380 💬 |
- |
- |
299 1件: 299 💬 |
381 |
Continuous infusion ticarcillin-clavulanate |
Clavulanic acid |
2件: D07711 D07711, D08593 D08593 💬 |
- |
- |
299 1件: 299 💬 |
382 |
Continuous intrajejunal infusion of levodopa-carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
383 |
Continuous oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
090 1件: 90 💬 |
384 |
Continuous release dopamine agonists |
Dopamine |
2件: D00633 D00633, D07870 D07870 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
385 |
Continuous subcutaneous lisuride infusion |
Lisuride |
2件: D01462 D01462, D08132 D08132 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
386 |
Contrast enhanced ultrasound |
- |
- |
- |
- |
096 1件: 96 💬 |
387 |
Control |
- |
- |
- |
- |
006 4件: 6 , 46, 168, 299 💬 |
388 |
Control group |
- |
- |
- |
- |
002 3件: 2 , 46, 70 💬 |
389 |
Control group 0.9% isotonic saline |
- |
- |
- |
- |
299 1件: 299 💬 |
390 |
Control intervention (no dexamethasone) |
Dexamethasone |
9件: D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
391 |
Control multivitamin |
- |
- |
- |
- |
299 1件: 299 💬 |
392 |
Controlled-release levodopa / carbidopa |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
393 |
Conventional |
- |
- |
- |
- |
063 1件: 63 💬 |
394 |
Conventional dmard combination |
- |
- |
- |
- |
046 1件: 46 💬 |
395 |
Conventional dmards |
- |
- |
- |
- |
046 1件: 46 💬 |
396 |
Conventional drug therapy(expectorant,bronchodilator) |
- |
- |
- |
- |
086 1件: 86 💬 |
397 |
Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) |
Acetate |
21件: D00088 D00088, D00292 D00292, D00472 D00472, D00473 D00473, D00973 D00973, D00975 D00975, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D01998 D01998, D02156 D02156, D02174 D02174, D02591 D02591, D02592 D02592, D03301 D03301, D07749 D07749 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
398 |
Conventional synthetic dmard |
- |
- |
- |
- |
046 1件: 46 💬 |
399 |
Conventional therapy |
- |
- |
- |
- |
067 2件: 67, 222 💬 |
400 |
Coozar |
- |
- |
- |
- |
167 1件: 167 💬 |
401 |
Cop |
- |
- |
- |
- |
013 1件: 13 💬 |
402 |
Cop-1 |
Glatiramer |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
403 |
Cop-1/copolymer-1 |
Glatiramer |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
404 |
Copaxone |
- |
- |
- |
- |
013 1件: 13 💬 |
405 |
Copaxone - 20 mg/ml soluzione iniettabile in siringhe preriempite 30 siringhe |
- |
- |
- |
- |
013 1件: 13 💬 |
406 |
Copaxone - 40 mg/ml soluzione iniettabile in siringa preriempita 12 siringhe preriempite da 1 ml con ago |
- |
- |
- |
- |
013 1件: 13 💬 |
407 |
Copaxone 20 mg |
- |
- |
- |
- |
013 1件: 13 💬 |
408 |
Copaxone 20 mg/ml |
- |
- |
- |
- |
013 1件: 13 💬 |
409 |
Copaxone 20 mg/ml solución inyectable en jeringa precargada |
- |
- |
- |
- |
013 1件: 13 💬 |
410 |
Copaxone 20 mg/ml solución para inyección en jeringa precargada |
- |
- |
- |
- |
013 1件: 13 💬 |
411 |
Copaxone 20 mg/ml solution for injection, pre-filled syringe |
- |
- |
- |
- |
013 1件: 13 💬 |
412 |
Copaxone 20 mg/ml, solution for injection, pre-filled syringes |
- |
- |
- |
- |
013 1件: 13 💬 |
413 |
Copaxone 20mg/ml solution for injection, pre-filled syringe |
- |
- |
- |
- |
013 1件: 13 💬 |
414 |
Copaxone 40 mg/ml |
- |
- |
- |
- |
013 1件: 13 💬 |
415 |
Copaxone 40 mg/ml solution for injection, pre-filled syringe |
- |
- |
- |
- |
013 1件: 13 💬 |
416 |
Copaxone subcutaneous injection syringe |
- |
- |
- |
- |
013 1件: 13 💬 |
417 |
Copaxone*sc 28sir 20mg/ml |
- |
- |
- |
- |
013 1件: 13 💬 |
418 |
Copaxone-teva |
- |
- |
- |
- |
013 1件: 13 💬 |
419 |
Copaxone® |
- |
- |
- |
- |
013 1件: 13 💬 |
420 |
Copegus |
- |
- |
- |
- |
002 1件: 2 💬 |
421 |
Copolymer 1 |
- |
- |
- |
- |
013 1件: 13 💬 |
422 |
Copolymer-1 |
Glatiramer |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
423 |
Copper |
Copper |
- |
- |
- |
002 4件: 2 , 169, 170, 171 💬 |
424 |
Copper (64cu) chloride |
Chloride ion |
- |
- |
- |
171 1件: 171 💬 |
425 |
Copper histidinate |
Copper |
- |
- |
- |
169 1件: 169 💬 |
426 |
Copper histidine |
Copper |
1件: D00032 D00032 💬 |
- |
- |
169 2件: 169, 170 💬 |
427 |
Coq10 |
- |
- |
- |
- |
005 3件: 5 , 6 , 8 💬 |
428 |
Coqun |
- |
- |
- |
- |
090 1件: 90 💬 |
429 |
Cor-003 |
- |
- |
- |
- |
075 1件: 75 💬 |
430 |
Cord blood |
- |
- |
- |
- |
060 1件: 60 💬 |
431 |
Cord blood therapy |
Umbilical Cord Blood Hematopoietic Stem Cells |
- |
- |
- |
002 2件: 2 , 6 💬 |
432 |
Cord blood transplant |
- |
- |
- |
- |
060 1件: 60 💬 |
433 |
Cord blood units |
- |
- |
- |
- |
060 1件: 60 💬 |
434 |
Cordin |
- |
- |
- |
- |
060 1件: 60 💬 |
435 |
Corn |
Corn |
- |
- |
- |
046 2件: 46, 240 💬 |
436 |
Corn oil capsules |
Corn |
- |
- |
- |
046 1件: 46 💬 |
437 |
Corn starch |
Starch, corn |
1件: D05297 D05297 💬 |
- |
- |
049 1件: 49 💬 |
438 |
Corn/soy oil |
Corn |
- |
- |
- |
240 1件: 240 💬 |
439 |
Cornstarch |
Starch, corn |
1件: D05297 D05297 💬 |
- |
- |
090 2件: 90, 257 💬 |
440 |
Cornstarch control |
Starch, corn |
1件: D05297 D05297 💬 |
- |
- |
090 1件: 90 💬 |
441 |
Cort125134 |
Relacorilant |
1件: D11336 D11336 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
075 1件: 75 💬 |
442 |
Cortancyl |
Prednisone acetate |
1件: D08416 D08416 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
035 3件: 35, 41, 162 💬 |
443 |
Cortancyl 20 mg |
Prednisone acetate |
1件: D08416 D08416 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
035 2件: 35, 162 💬 |
444 |
Cortancyl ® 1 mg |
Prednisone acetate |
1件: D08416 D08416 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
041 1件: 41 💬 |
445 |
Cortancyl ® 20 mg |
Prednisone acetate |
1件: D08416 D08416 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
041 1件: 41 💬 |
446 |
Cortancyl ® 5 mg |
Prednisone acetate |
1件: D08416 D08416 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
041 1件: 41 💬 |
447 |
Cortecosteroid |
- |
- |
- |
- |
096 1件: 96 💬 |
448 |
Cortef |
- |
- |
- |
- |
006 3件: 6 , 81, 83 💬 |
449 |
Cortef (hydrocortisone) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
450 |
Cortef 5 mg |
- |
- |
- |
- |
083 1件: 83 💬 |
451 |
Corticoids+ tocilizumab 8mg/kg/4 weeks |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
041 1件: 41 💬 |
452 |
Corticosteroid |
- |
- |
- |
- |
013 10件: 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 💬 |
453 |
Corticosteroid (cs) |
- |
- |
- |
- |
041 1件: 41 💬 |
454 |
Corticosteroid (prednisolone) |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
085 1件: 85 💬 |
455 |
Corticosteroid and azathioprine |
Azathioprine |
2件: D00238 D00238, D03033 D03033 💬 |
- |
- |
042 4件: 42, 43, 44, 45 💬 |
456 |
Corticosteroid and non-biological agents. |
- |
- |
- |
- |
046 1件: 46 💬 |
457 |
Corticosteroid or nsaid |
- |
- |
- |
- |
046 1件: 46 💬 |
458 |
Corticosteroid treatment (methylprednisolone or prednisolone) |
Methylprednisolone |
14件: D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
064 1件: 64 💬 |
459 |
Corticosteroids |
- |
- |
- |
- |
041 10件: 41, 46, 49, 64, 97, 107, 164, 220, 296, 300 💬 |
460 |
Corticosteroids & tancart19/20 |
- |
- |
- |
- |
013 1件: 13 💬 |
461 |
Corticosteroids (aprednislon) |
- |
- |
- |
- |
063 1件: 63 💬 |
462 |
Corticosteroids (prednisone or prednisolone) |
Prednisolone |
9件: D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
049 1件: 49 💬 |
463 |
Corticosteroids for systemic use |
- |
- |
- |
- |
041 1件: 41 💬 |
464 |
Corticosteroids only |
- |
- |
- |
- |
097 1件: 97 💬 |
465 |
Corticosteroids'therapy |
- |
- |
- |
- |
035 1件: 35 💬 |
466 |
Corticotherapy |
- |
- |
- |
- |
066 1件: 66 💬 |
467 |
Corticotrophin |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
046 1件: 46 💬 |
468 |
Corticotrophin 80 units |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
046 1件: 46 💬 |
469 |
Corticotropin |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
002 7件: 2 , 13, 46, 75, 78, 84, 222 💬 |
470 |
Corticotropin-releasing hormone |
Corticorelin |
2件: D00146 D00146, D03905 D03905 💬 |
CRHR1 3件: CRHR1, CRHR2, MC2R 💬 |
Aldosterone synthesis and secretion 6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
075 1件: 75 💬 |
471 |
Cortimentmmx 9 mg |
- |
- |
- |
- |
097 1件: 97 💬 |
472 |
Cortisol |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
473 |
Cortison |
- |
- |
- |
- |
081 1件: 81 💬 |
474 |
Cortisone |
Cortisone |
1件: D07749 D07749 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
475 |
Cortisone acetate |
Acetate |
2件: D00973 D00973, D07749 D07749 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
476 |
Cosentyx |
- |
- |
- |
- |
041 3件: 41, 269, 271 💬 |
477 |
Cosentyx® |
- |
- |
- |
- |
269 1件: 269 💬 |
478 |
Cosmofer |
- |
- |
- |
- |
086 3件: 86, 96, 97 💬 |
479 |
Cosmofer 50mg/ml solution for infusion or injection |
- |
- |
- |
- |
096 2件: 96, 97 💬 |
480 |
Costicosteroids |
- |
- |
- |
- |
026 1件: 26 💬 |
481 |
Cosyntropin |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 3件: 83, 113, 145 💬 |
482 |
Cosyntropin acetate |
Acetate |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
113 1件: 113 💬 |
483 |
Cosyntropin injectable suspension 1 mg/ml + vigabatrin |
Tetracosactide |
2件: D00284 D00284, D00535 D00535 💬 |
ABAT 2件: ABAT, MC2R 💬 |
Alanine, aspartate and glutamate metabolism 12件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, cAMP signaling pathway |
145 1件: 145 💬 |
484 |
Cosyntropin injectable suspension, 1 mg/ml |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
145 1件: 145 💬 |
485 |
Cotrimoxazole |
- |
- |
- |
- |
085 2件: 85, 97 💬 |
486 |
Cotton |
Cotton |
- |
- |
- |
035 2件: 35, 162 💬 |
487 |
Coversin |
Nomacopan |
1件: D11473 D11473 💬 |
C5 1件: C5 💬 |
Complement and coagulation cascades 9件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 2件: 62, 109 💬 |
488 |
Coversyl |
- |
- |
- |
- |
019 2件: 19, 167 💬 |
489 |
Coversyl (perindopril) |
Perindopril |
2件: D00624 D00624, D03753 D03753 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
167 1件: 167 💬 |
490 |
Coversyl plus |
- |
- |
- |
- |
019 1件: 19 💬 |
491 |
Cozaar |
- |
- |
- |
- |
167 1件: 167 💬 |
492 |
Cozaar 50 |
- |
- |
- |
- |
167 1件: 167 💬 |
493 |
Cozaar 50 mg comprimidos recubierto con pelicula |
- |
- |
- |
- |
179 1件: 179 💬 |
494 |
Cozaar inicio 12,5 mg comprimidos recubiertos con pelicula |
- |
- |
- |
- |
167 1件: 167 💬 |
495 |
Crestor film-coated tablet |
- |
- |
- |
- |
079 1件: 79 💬 |
496 |
Crestor tablets (calcium rosuvastatin) film-coated tablets |
Calcium |
2件: D01915 D01915, D08492 D08492 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
079 1件: 79 💬 |
497 |
Cryopreserved autologous cd34+ cells transduced with a lentiviral vector containing human sgsh gene |
- |
- |
- |
- |
019 1件: 19 💬 |
498 |
Cs (corticosteroids) only |
- |
- |
- |
- |
097 1件: 97 💬 |
499 |
Csm allogéniques issues de cordons ombilicaux ( mti-pp) |
- |
- |
- |
- |
049 1件: 49 💬 |
500 |
Cumulative corticosteroid exposure |
- |
- |
- |
- |
049 1件: 49 💬 |
501 |
Cuprior 150 mg film-coated tablets |
- |
- |
- |
- |
171 1件: 171 💬 |
502 |
Cuprior 150mg film-coated tablets |
- |
- |
- |
- |
171 1件: 171 💬 |
503 |
Currently available therapy in the community |
- |
- |
- |
- |
051 1件: 51 💬 |
504 |
Cushing's syndrome confirmation |
- |
- |
- |
- |
075 1件: 75 💬 |
505 |
Cyclophosphamide/glatiramer acetate |
Acetate |
3件: D00287 D00287, D04318 D04318, D07760 D07760 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
506 |
Cyclosporine combine with mycophenolate mofetil |
Cyclosporine |
5件: D00184 D00184, D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 7件: IMPDH1, IMPDH2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 35件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
283 1件: 283 💬 |
507 |
Cytotoxic combination |
- |
- |
- |
- |
056 1件: 56 💬 |
508 |
D-methylphenidate |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
509 |
D-sorbitol |
Sorbitol |
1件: D00096 D00096 💬 |
- |
- |
010 1件: 10 💬 |
510 |
D.3.2 product code where applicable13: |
- |
- |
- |
- |
193 1件: 193 💬 |
511 |
Daratumumab co-formulated with recombinant human hyaluronidase (rhuph20) |
Daratumumab |
4件: D04455 D04455, D04456 D04456, D06604 D06604, D10777 D10777 💬 |
CD38 1件: CD38 💬 |
Calcium signaling pathway 7件: Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion |
028 1件: 28 💬 |
512 |
Dark chocolate (85% cocoa) |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
513 |
Data collection |
- |
- |
- |
- |
065 1件: 65 💬 |
514 |
Decortin (prednisona) 5 mg comprimidos |
Prednisone |
1件: D00473 D00473 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
515 |
Depot tetracosactide |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 1件: 83 💬 |
516 |
Device: 129xe small and large human lung coil |
- |
- |
- |
- |
299 1件: 299 💬 |
517 |
Device: 3he human lung coil |
- |
- |
- |
- |
299 1件: 299 💬 |
518 |
Device: abatacept combination product (acp) |
Abatacept |
1件: D03203 D03203 💬 |
CD80 2件: CD80, CD86 💬 |
Allograft rejection 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
046 1件: 46 💬 |
519 |
Device: abdominal compression |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
520 |
Device: auto-titrating oxygen system |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
085 1件: 85 💬 |
521 |
Device: c-stem™ amt femoral component (standard and high off-set variants) |
- |
- |
- |
- |
046 1件: 46 💬 |
522 |
Device: capacity of muscular oxygen extraction |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
013 1件: 13 💬 |
523 |
Device: cellvizio 100 series system with confocal miniprobes |
- |
- |
- |
- |
215 1件: 215 💬 |
524 |
Device: cervical orthosis (co) |
- |
- |
- |
- |
070 1件: 70 💬 |
525 |
Device: cobalt™ bone cement |
Cobalt |
- |
- |
- |
046 1件: 46 💬 |
526 |
Device: continuous glucose monitor |
Dextrose, unspecified form |
- |
- |
- |
065 1件: 65 💬 |
527 |
Device: continuous glucose monitor (cgm) |
Dextrose, unspecified form |
- |
- |
- |
299 1件: 299 💬 |
528 |
Device: continuous glucose monitoring |
Dextrose, unspecified form |
- |
- |
- |
075 2件: 75, 299 💬 |
529 |
Device: contrast enhanced ultrasound |
- |
- |
- |
- |
096 1件: 96 💬 |
530 |
Device: conventional syringe - bd ref 309604 |
- |
- |
- |
- |
046 1件: 46 💬 |
531 |
Device: cotton gauze with petrolatum |
Cotton |
2件: D05304 D05304, D05331 D05331 💬 |
- |
- |
035 2件: 35, 162 💬 |
532 |
Device: fourier domain doppler optical coherence tomography (fdoct) |
- |
- |
- |
- |
013 1件: 13 💬 |
533 |
Device: high flow nasal oxygen cannula |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
534 |
Device: high-resolution peripheral quantitative computed tomography (hr-pqct) |
- |
- |
- |
- |
046 1件: 46 💬 |
535 |
Device: hyperbaric oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
046 1件: 46 💬 |
536 |
Device: in utero endoscopic correction of myelomeningocele ide - laparotomy/uterine exteriorization technique |
- |
- |
- |
- |
118 1件: 118 💬 |
537 |
Device: in utero endoscopic correction of myelomeningocele ide - percutaneous technique |
- |
- |
- |
- |
118 1件: 118 💬 |
538 |
Device: intermittent exposure to oxygen via oro-nasal mask |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
226 1件: 226 💬 |
539 |
Device: light box ( litebook company) |
- |
- |
- |
- |
006 1件: 6 💬 |
540 |
Device: light box (litebook company) |
- |
- |
- |
- |
006 1件: 6 💬 |
541 |
Device: manual toothbrush and water flosser (philips sonicare airfloss) |
Water |
1件: D00001 D00001 💬 |
- |
- |
051 1件: 51 💬 |
542 |
Device: mri with contrast agent injection |
- |
- |
- |
- |
019 1件: 19 💬 |
543 |
Device: mri without contrast agent injection |
- |
- |
- |
- |
019 1件: 19 💬 |
544 |
Device: nocturnal oxygen , nocturnal bi-level positive pressure ventilation |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
545 |
Device: optical coherence tomography (oct) |
- |
- |
- |
- |
013 1件: 13 💬 |
546 |
Device: optical coherence tomography angiography (octa) |
- |
- |
- |
- |
013 1件: 13 💬 |
547 |
Device: oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
548 |
Device: oxygen saturation |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
084 1件: 84 💬 |
549 |
Device: oxymizer® compared to cnc |
- |
- |
- |
- |
085 1件: 85 💬 |
550 |
Device: pfp and sf6 human lung coil |
- |
- |
- |
- |
299 1件: 299 💬 |
551 |
Device: sham compression |
- |
- |
- |
- |
006 2件: 6 , 17 💬 |
552 |
Device: sonic toothbrush (philips sonicare) and water flosser (philips sonicare airfloss) |
Water |
1件: D00001 D00001 💬 |
- |
- |
051 1件: 51 💬 |
553 |
Device: standard oxygen therapy/ra |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
554 |
Device: the colonic transendoscopic enteral tubing. |
- |
- |
- |
- |
097 1件: 97 💬 |
555 |
Device: voluntary peak cough flow testing |
- |
- |
- |
- |
002 1件: 2 💬 |
556 |
Dexamethasone (50mg 1dd6, 3 consecutive days/month) |
Dexamethasone |
9件: D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
035 1件: 35 💬 |
557 |
Dextrose, 5% in water |
Dextrose, unspecified form |
1件: D00001 D00001 💬 |
- |
- |
065 1件: 65 💬 |
558 |
Diagnostic test: adalimumab serum trough concentration |
Adalimumab |
1件: D02597 D02597 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
559 |
Diagnostic test: adalimumab trough concentration |
Adalimumab |
1件: D02597 D02597 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
560 |
Diagnostic test: blood drawing in healthy controls |
- |
- |
- |
- |
065 1件: 65 💬 |
561 |
Diagnostic test: colchicine level measurement |
Colchicine |
1件: D00570 D00570 💬 |
TUBB 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 |
Alzheimer disease 10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection |
266 1件: 266 💬 |
562 |
Diagnostic test: colonoscopy |
- |
- |
- |
- |
097 1件: 97 💬 |
563 |
Diagnostic test: continuous glucose monitoring |
Dextrose, unspecified form |
- |
- |
- |
299 1件: 299 💬 |
564 |
Diagnostic test: cosyntropin stimulation test |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 1件: 83 💬 |
565 |
Diagnostic test: fibrinogen plasma concentration, coagulation factor xiii activity |
Factor XIII (human) |
- |
- |
- |
288 1件: 288 💬 |
566 |
Diagnostic test: maximum oxygen uptake |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
294 1件: 294 💬 |
567 |
Diagnostic test: mini cognitive examination (mce) |
- |
- |
- |
- |
006 1件: 6 💬 |
568 |
Diagnostic test: ocular coherence tomography-angiography (oct-a) |
- |
- |
- |
- |
090 2件: 90, 301 💬 |
569 |
Diagnostic test: p-mpa concentration |
- |
- |
- |
- |
051 1件: 51 💬 |
570 |
Diagnostic test: parasitological diagnostics (coproscopy) |
- |
- |
- |
- |
097 1件: 97 💬 |
571 |
Diagnostic test: rey-osterrieth complex figure test (rocft) |
- |
- |
- |
- |
006 1件: 6 💬 |
572 |
Diagnostic test: serum metal ion levels determined to monitor changes in chromium and cobalt levels |
Chromium |
- |
- |
- |
046 1件: 46 💬 |
573 |
Diagnostic test: simultaneous combined 18f-fdg pet and cardiac mri imaging |
Fludeoxyglucose (18F) |
- |
- |
- |
084 1件: 84 💬 |
574 |
Diagnostic test: spanish-complutense verbal learning test (tavec) |
- |
- |
- |
- |
006 1件: 6 💬 |
575 |
Diazoxide choline controlled-release tablet |
Choline |
2件: D00294 D00294, D07690 D07690 💬 |
ABCC8 2件: ABCC8, KCNJ11 💬 |
ABC transporters 4件: ABC transporters, GnRH secretion, Insulin secretion, Type II diabetes mellitus |
193 1件: 193 💬 |
576 |
Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon |
Ammonium chloride |
1件: D01139 D01139 💬 |
- |
- |
096 1件: 96 💬 |
577 |
Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias) |
Amiodarone |
2件: D00636 D00636, D02910 D02910 💬 |
ADRA1A 16件: ADRA1A, ADRA1B, ADRA1D, ADRB1, KCND3, KCNJ11, KCNJ12, KCNJ3, KCNJ5, KCNJ8, KCNQ1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
AMPK signaling pathway 31件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Dilated cardiomyopathy, Dopaminergic synapse, Estrogen signaling pathway, Gap junction, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, Insulin secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Pancreatic secretion, Protein digestion and absorption, Regulation of lipolysis in adipocytes, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Type II diabetes mellitus, Vascular smooth muscle contraction, Vibrio cholerae infection, cAMP signaling pathway, cGMP-PKG signaling pathway |
028 1件: 28 💬 |
578 |
Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus egcg |
Amiodarone |
2件: D00636 D00636, D02910 D02910 💬 |
ADRA1A 16件: ADRA1A, ADRA1B, ADRA1D, ADRB1, KCND3, KCNJ11, KCNJ12, KCNJ3, KCNJ5, KCNJ8, KCNQ1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
AMPK signaling pathway 31件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Dilated cardiomyopathy, Dopaminergic synapse, Estrogen signaling pathway, Gap junction, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, Insulin secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Pancreatic secretion, Protein digestion and absorption, Regulation of lipolysis in adipocytes, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Type II diabetes mellitus, Vascular smooth muscle contraction, Vibrio cholerae infection, cAMP signaling pathway, cGMP-PKG signaling pathway |
028 1件: 28 💬 |
579 |
Dmso cocktail |
Dimethyl sulfoxide |
1件: D01043 D01043 💬 |
- |
- |
226 1件: 226 💬 |
580 |
Dmt continuation |
- |
- |
- |
- |
013 1件: 13 💬 |
581 |
Doptelet 20 mg film-coated tablets |
- |
- |
- |
- |
063 1件: 63 💬 |
582 |
Drug free, is monotherapy and gc combined with is |
- |
- |
- |
- |
300 1件: 300 💬 |
583 |
Dual release hydrocortisone (plenadren) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
584 |
E. coli nissle |
- |
- |
- |
- |
097 1件: 97 💬 |
585 |
Echo and myocardial contrast echocardiography perfusion imaging |
- |
- |
- |
- |
058 1件: 58 💬 |
586 |
Eflornithine plus nifurtimox combination therapy |
Eflornithine |
2件: D00833 D00833, D07883 D07883 💬 |
ODC1 1件: ODC1 💬 |
Arginine and proline metabolism 3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 1件: 65 💬 |
587 |
Eltrombopag combining rituximab |
Eltrombopag |
2件: D02994 D02994, D03978 D03978 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
063 1件: 63 💬 |
588 |
Enalapril and other angiotensin converting enzyme inhibitors |
Angiotensin II |
4件: D00150 D00150, D00621 D00621, D02014 D02014, D07892 D07892 💬 |
ACE 3件: ACE, AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 1件: 19 💬 |
589 |
Endoprost - 0.05 mg/0.5 ml concentrato per soluzione per infusione 1 fiala |
- |
- |
- |
- |
051 1件: 51 💬 |
590 |
Entacapone |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
591 |
Entacapone 400mg oral dose |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 2件: 6 , 17 💬 |
592 |
Entacapone and carbidopa |
Carbidopa |
2件: D00558 D00558, D00781 D00781 💬 |
COMT 2件: COMT, DDC 💬 |
Alcoholism 10件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
593 |
Entacapone inn |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
594 |
Enteric coated mycophenolate sodium |
Mycophenolic acid |
1件: D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
228 1件: 228 💬 |
595 |
Enteric-coated mycophenolate sodium |
Mycophenolic acid |
1件: D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
049 1件: 49 💬 |
596 |
Epilim chrono 200 controlled released tablets |
- |
- |
- |
- |
256 1件: 256 💬 |
597 |
Epilim chrono 300 controlled released tablets |
- |
- |
- |
- |
256 1件: 256 💬 |
598 |
Epilim chrono 500 controlled released tablets |
- |
- |
- |
- |
256 1件: 256 💬 |
599 |
Epinephrine |
Epinephrine |
3件: D00095 D00095, D00996 D00996, D02149 D02149 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 2件: 46, 96 💬 |
600 |
Etanercept, methotrexate, prednisolone |
Etanercept |
11件: D00142 D00142, D00472 D00472, D00742 D00742, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02115 D02115, D02156 D02156, D03301 D03301 💬 |
DHFR 5件: DHFR, DHFR2, LTA, NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 70件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
056 1件: 56 💬 |
601 |
Etims (edc-fixed autologous pbmcs coupled with 7 immunodominant myelin peptides in ms patients) |
- |
- |
- |
- |
013 1件: 13 💬 |
602 |
Ev substance code: sub188638 |
- |
- |
- |
- |
113 1件: 113 💬 |
603 |
Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length lamb3 cdna. |
- |
- |
- |
- |
036 1件: 36 💬 |
604 |
Experimental glatiramer acetate |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
605 |
Extension cohort |
- |
- |
- |
- |
060 1件: 60 💬 |
606 |
Ezetimibe+simvastatin drug combination |
Ezetimibe |
2件: D00434 D00434, D01966 D01966 💬 |
HMGCR 2件: HMGCR, NPC1L1 💬 |
AMPK signaling pathway 5件: AMPK signaling pathway, Bile secretion, Fat digestion and absorption, Metabolic pathways, Terpenoid backbone biosynthesis |
049 1件: 49 💬 |
607 |
Fabrazyme - 35 mg polvere per concentrato per soluzione per infusione endovenosa 1 flaconcino |
- |
- |
- |
- |
019 1件: 19 💬 |
608 |
Factor viii concentrate |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
609 |
Factor xiii concentrate (human) |
Factor XIII (human) |
- |
- |
- |
288 1件: 288 💬 |
610 |
Factor xiii concentrate (human), pasteurized |
Factor XIII (human) |
- |
- |
- |
288 1件: 288 💬 |
611 |
Fampyra - 10 mg - compressa a rilascio prolungato - uso orale - flacone (hdpe) 56 compresse (4 flaconi da 14) |
- |
- |
- |
- |
013 1件: 13 💬 |
612 |
Fdl176 & fdl169 coadministration |
- |
- |
- |
- |
299 1件: 299 💬 |
613 |
Fenfluramine hydrochloride (colorless) |
Fenfluramine |
1件: D07945 D07945 💬 |
HTR2A 4件: HTR2A, HTR2B, HTR2C, SLC6A4 💬 |
Calcium signaling pathway 6件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
140 2件: 140, 144 💬 |
614 |
Ferinject or cosmofer |
- |
- |
- |
- |
086 1件: 86 💬 |
615 |
Fibrinogen (coagulation factori) |
Fibrinogen human |
- |
- |
- |
065 1件: 65 💬 |
616 |
Fibrinogen concentrate |
Fibrinogen human |
- |
- |
- |
014 1件: 14 💬 |
617 |
Fibrinogen concentrate from human plasma |
Fibrinogen human |
- |
- |
- |
065 1件: 65 💬 |
618 |
Fibrogammin®p, coagulation factor xiii concentrate (human) |
Factor XIII (human) |
- |
- |
- |
051 1件: 51 💬 |
619 |
Film-coated tablet |
- |
- |
- |
- |
097 1件: 97 💬 |
620 |
Fipamezole odt cohort 2 |
Fipamezole |
- |
- |
- |
006 1件: 6 💬 |
621 |
Firdapse - 10 mg - compresse - uso orale - blister(alu/pvc/pvdc) 100 x 1 compresse |
- |
- |
- |
- |
011 1件: 11 💬 |
622 |
Fish oil concentrate |
Fish oil |
- |
- |
- |
013 1件: 13 💬 |
623 |
Fixed dose combination ciprofloxacin/celecoxib |
Celecoxib |
3件: D00186 D00186, D00567 D00567, D02216 D02216 💬 |
PTGS2 1件: PTGS2 💬 |
Alzheimer disease 22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
002 1件: 2 💬 |
624 |
Flaxseed lignan-enriched complex (flc) |
- |
- |
- |
- |
097 1件: 97 💬 |
625 |
Fludarabina accord - 25 mg/ml concentrato per soluzione iniettabile o per infusione 5 flaconcini in vetro da 2 ml |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 1件: 19 💬 |
626 |
Fludarabina teva - 25 mg/ml concentrato per soluzione iniettabile o per infusione 1 flaconcino di vetro da 2 ml |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
065 1件: 65 💬 |
627 |
Formistin - 10 mg compresse rivestite con film 20 compresse |
- |
- |
- |
- |
013 1件: 13 💬 |
628 |
Fostamatinib 50 mg blue film-coated tablet |
Fostamatinib |
1件: D09347 D09347 💬 |
SYK 1件: SYK 💬 |
B cell receptor signaling pathway 17件: B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis |
046 1件: 46 💬 |
629 |
Fxiii concentrate (human) |
- |
- |
- |
- |
288 1件: 288 💬 |
630 |
Fxiii concentrate (human) (fxiii) |
- |
- |
- |
- |
288 1件: 288 💬 |
631 |
G-csf for conditioning before hsct. |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 1件: 65 💬 |
632 |
Gaboxadol monohydrate 0.5 mg (intended commercial formulation) |
Gaboxadol |
1件: D04282 D04282 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
201 1件: 201 💬 |
633 |
Gaboxadol monohydrate 2 mg (intended commercial formulation) |
Gaboxadol |
1件: D04282 D04282 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
201 1件: 201 💬 |
634 |
Gaboxadol monohydrate 5 mg (intended commercial formulation) |
Gaboxadol |
1件: D04282 D04282 💬 |
GABRA1 16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
201 1件: 201 💬 |
635 |
Gadolinium contrast |
Gadolinium |
- |
- |
- |
034 1件: 34 💬 |
636 |
Gadolinium-based contrast |
Gadolinium |
- |
- |
- |
013 1件: 13 💬 |
637 |
Gelatin |
Gelatin |
2件: D00115 D00115, D06892 D06892 💬 |
- |
- |
028 4件: 28, 78, 97, 269 💬 |
638 |
General corticotherapy |
- |
- |
- |
- |
035 1件: 35 💬 |
639 |
Genetic: amplification by pcr and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene |
- |
- |
- |
- |
265 1件: 265 💬 |
640 |
Genetic: blood or saliva sample collection |
- |
- |
- |
- |
299 1件: 299 💬 |
641 |
Genetic: recombinant adenovirus containing the ornithine transcarbamylase gene |
Ornithine |
1件: D08302 D08302 💬 |
- |
- |
251 1件: 251 💬 |
642 |
Genetically corrected cultured epidermal autograft (atmp) |
- |
- |
- |
- |
036 1件: 36 💬 |
643 |
Genotropin (somatropin) is a growth hormone treatment. it is an exact copy of the natural growth hormone that our bodies make. the main difference is that genotropin is man-made. |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
193 1件: 193 💬 |
644 |
Glatiramer |
Glatiramer |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
002 4件: 2 , 13, 96, 156 💬 |
645 |
Glatiramer acetate |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 3件: 13, 96, 156 💬 |
646 |
Glatiramer acetate (copaxone®) |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 2件: 13, 156 💬 |
647 |
Glatiramer acetate (db) |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
648 |
Glatiramer acetate (ga) |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
649 |
Glatiramer acetate (ga) 40 mg |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
650 |
Glatiramer acetate (gtr) |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
651 |
Glatiramer acetate (ol) |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
652 |
Glatiramer acetate 150mg enteric coated tablets |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
653 |
Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
654 |
Glatiramer acetate 20 mg |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
655 |
Glatiramer acetate 20 mg, with mitoxantrone |
Acetate |
3件: D02166 D02166, D04318 D04318, D08224 D08224 💬 |
HLA-A 22件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, TOP2A, TOP2B 💬 |
Allograft rejection 33件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Platinum drug resistance, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
656 |
Glatiramer acetate 20 mg/0.5 ml |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
657 |
Glatiramer acetate 40 mg |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
658 |
Glatiramer acetate [ga] |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
659 |
Glatiramer acetate injection with oral cetirizine hydrochloride |
Acetate |
3件: D00664 D00664, D04318 D04318, D07662 D07662 💬 |
HLA-A 21件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, HRH1 💬 |
Allograft rejection 35件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Calcium signaling pathway, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
660 |
Glatiramer acetate with minocycline |
Acetate |
3件: D00850 D00850, D04318 D04318, D05045 D05045 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
661 |
Glatiramer acetate, (copaxone®) |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
662 |
Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
663 |
Glatiramer acetate, n-acetylcysteine |
Acetate |
2件: D00221 D00221, D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
664 |
Glatiramer acetato |
Glatiramer |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
665 |
Glivec 100 mg comprimidos recubiertos con película |
- |
- |
- |
- |
034 2件: 34, 86 💬 |
666 |
Glivec 400 mg comprimidos recubiertos con película |
- |
- |
- |
- |
034 1件: 34 💬 |
667 |
Glucocorticoid (prednisone or prednisolone) |
Prednisolone |
9件: D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
084 1件: 84 💬 |
668 |
Gm-csf (granulocyte-macrophage colony-stimulating factor, sargramostim) |
Sargramostim |
1件: D05803 D05803 💬 |
CSF2RA 1件: CSF2RA 💬 |
Cytokine-cytokine receptor interaction 4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
229 1件: 229 💬 |
669 |
Granulocyte - colony stimulating factor (g-csf) |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 1件: 2 💬 |
670 |
Granulocyte colony stimulating factor |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 6件: 2 , 28, 36, 57, 65, 85 💬 |
671 |
Granulocyte colony stimulating factor (g-csf) |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
065 1件: 65 💬 |
672 |
Granulocyte colony stimulating factor (gcsf) |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
036 2件: 36, 57 💬 |
673 |
Granulocyte colony-stimulating factor |
- |
- |
- |
- |
296 1件: 296 💬 |
674 |
Granulocyte colony-stimulating factor (filgrastim) |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
113 1件: 113 💬 |
675 |
Granulocyte-colony stimulating factor (g-csf) and prednisone |
Filgrastim |
2件: D00473 D00473, D03235 D03235 💬 |
CSF3R 2件: CSF3R, NR3C1 💬 |
Cytokine-cytokine receptor interaction 6件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pathways in cancer |
013 1件: 13 💬 |
676 |
Granulocyte-macrophage colony stimulating factor (gm-csf) |
- |
- |
- |
- |
229 1件: 229 💬 |
677 |
Granulocyte-macrophage colony-stimulating factor (gm-csf) |
- |
- |
- |
- |
011 1件: 11 💬 |
678 |
Group 1- control diet |
- |
- |
- |
- |
097 1件: 97 💬 |
679 |
Growth colony stimulating factor (g-csf) |
Filgrastim |
1件: D03235 D03235 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
049 1件: 49 💬 |
680 |
Gsk1265744b (sodium salt) containing 14c-gsk1265744b |
- |
- |
- |
- |
265 1件: 265 💬 |
681 |
H.p. acthar gel (repository corticotropin injection) |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
013 1件: 13 💬 |
682 |
Haemate p® (human coagulation factor viii) |
Antihemophilic factor human |
- |
- |
- |
288 1件: 288 💬 |
683 |
Haplo/cord transplant |
- |
- |
- |
- |
060 1件: 60 💬 |
684 |
Hcq/cq and cab combined treatment |
- |
- |
- |
- |
074 1件: 74 💬 |
685 |
Helium / oxygen mixed gas inhalation therapy |
Helium |
2件: D00003 D00003, D04420 D04420 💬 |
- |
- |
330 1件: 330 💬 |
686 |
Heparin & alkalinized lidocaine bladder instillation |
Heparin |
4件: D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A 6件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes 4件: Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
687 |
High dose vehicle control |
- |
- |
- |
- |
046 1件: 46 💬 |
688 |
High water intake |
Water |
1件: D00001 D00001 💬 |
- |
- |
067 1件: 67 💬 |
689 |
Hiomega-3 supplement of naturalis® company - |
- |
- |
- |
- |
049 1件: 49 💬 |
690 |
Histamine |
Histamine |
1件: D08040 D08040 💬 |
HRH1 4件: HRH1, HRH2, HRH3, HRH4 💬 |
Calcium signaling pathway 4件: Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
013 1件: 13 💬 |
691 |
Hmg-coenzyme inhibitor (statin) |
- |
- |
- |
- |
218 1件: 218 💬 |
692 |
Hov-12020 (palm tocotrienols complex) |
- |
- |
- |
- |
124 1件: 124 💬 |
693 |
Human coagulation factor viii |
Antihemophilic factor human |
- |
- |
- |
288 1件: 288 💬 |
694 |
Human coagulation factor viii / von willebrand factor |
Antihemophilic factor human |
- |
- |
- |
288 1件: 288 💬 |
695 |
Human coagulation factor viii associated with von willebrand factor (vwf) |
Antihemophilic factor human |
- |
- |
- |
288 1件: 288 💬 |
696 |
Human coagulation factor viii, von willebrand factor complex |
Antihemophilic factor human |
- |
- |
- |
288 1件: 288 💬 |
697 |
Human fibrinogen concentrate |
Fibrinogen human |
- |
- |
- |
065 1件: 65 💬 |
698 |
Human interferon beta-1a and glatiramer acetate |
Acetate |
2件: D04318 D04318, D04554 D04554 💬 |
HLA-A 22件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, IFNAR1, IFNAR2 💬 |
Allograft rejection 44件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
699 |
Human monoclonal antibody directed against complement 5 protein |
- |
- |
- |
- |
062 1件: 62 💬 |
700 |
Human umbilical cord blood-derived mesenchymal stem cells |
- |
- |
- |
- |
036 1件: 36 💬 |
701 |
Human umbilical cord derived msc transplantation for sle |
- |
- |
- |
- |
049 1件: 49 💬 |
702 |
Human umbilical cord mesenchymal stem cells |
Human Umbilical Cord Mesenchymal Stem Cells |
- |
- |
- |
013 2件: 13, 113 💬 |
703 |
Human umbilical cord-derived mscs |
- |
- |
- |
- |
271 1件: 271 💬 |
704 |
Human von willebrand factor (vwf) and coagulation factor viii (fviii) |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
705 |
Human vwf/fviii concentrate |
- |
- |
- |
- |
288 1件: 288 💬 |
706 |
Hydrocortisone |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 9件: 6 , 46, 53, 75, 78, 81, 83, 97, 299 💬 |
707 |
Hydrocortisone (solucortef) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
708 |
Hydrocortisone 100mg/ml |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
709 |
Hydrocortisone 10mg |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
710 |
Hydrocortisone 10mg tablet |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
711 |
Hydrocortisone 10mg tablets |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
712 |
Hydrocortisone 20mg tablets |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
713 |
Hydrocortisone acetate |
Acetate |
2件: D00088 D00088, D00165 D00165 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
714 |
Hydrocortisone cream |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
715 |
Hydrocortisone cream 1% |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
716 |
Hydrocortisone cream 10mg/g fna fagron |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
717 |
Hydrocortisone hydrogen succinate |
Hydrocortisone |
2件: D00088 D00088, D01442 D01442 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
718 |
Hydrocortisone modified release capsules |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
719 |
Hydrocortisone roussel |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
720 |
Hydrocortisone sodium acetate |
Acetate |
2件: D00088 D00088, D01779 D01779 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
721 |
Hydrocortisone sodium phosphate |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
053 3件: 53, 81, 83 💬 |
722 |
Hydrocortisone sodium succinate |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 3件: 81, 83, 97 💬 |
723 |
Hydrocortisone tablet 2.5 mg |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
724 |
Hydrocortisone takeda, tabletter |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
078 1件: 78 💬 |
725 |
Hyperglycemic clamp with concurrent gip infusion |
- |
- |
- |
- |
299 1件: 299 💬 |
726 |
Hyperglycemic clamp with concurrent glp-1 infusion |
- |
- |
- |
- |
299 1件: 299 💬 |
727 |
Hyperpolarized 129 xenon gas comparing idiopathic pulmonary fibrosis (ipf) treatment |
Xenon |
2件: D01901 D01901, D06339 D06339 💬 |
- |
- |
085 1件: 85 💬 |
728 |
Ic cocktail |
- |
- |
- |
- |
226 1件: 226 💬 |
729 |
Idebenone 150 mg film-coated tablets |
Idebenone |
1件: D01750 D01750 💬 |
- |
- |
113 1件: 113 💬 |
730 |
Immunosuppression only conditioning (ioc) |
- |
- |
- |
- |
065 1件: 65 💬 |
731 |
Immunosuppression only conditioning - closed with amendment l |
- |
- |
- |
- |
065 1件: 65 💬 |
732 |
Inflectra 100 mg powder for concentrate for solution for infusion |
- |
- |
- |
- |
096 2件: 96, 97 💬 |
733 |
Infliximab and azathioprine combination at week 0 |
Azathioprine |
3件: D00238 D00238, D02598 D02598, D03033 D03033 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
096 1件: 96 💬 |
734 |
Infliximab and azathioprine combination at week 14 |
Azathioprine |
3件: D00238 D00238, D02598 D02598, D03033 D03033 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
096 1件: 96 💬 |
735 |
Infliximab control |
Infliximab |
1件: D02598 D02598 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
736 |
Inhibace/cozaar |
- |
- |
- |
- |
066 1件: 66 💬 |
737 |
Injection of umbilical cord derived mscs |
- |
- |
- |
- |
006 1件: 6 💬 |
738 |
Inn colecalciferol |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 1件: 13 💬 |
739 |
Intra-articular compound betamethasone |
Betamethasone |
7件: D00244 D00244, D00972 D00972, D01357 D01357, D01402 D01402, D01637 D01637, D02032 D02032, D02286 D02286 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
740 |
Intraarticular morphine |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
741 |
Intravenous methyl prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
043 1件: 43 💬 |
742 |
Iron sucrose |
Iron sucrose |
2件: D00025 D00025, D04616 D04616 💬 |
- |
- |
062 3件: 62, 96, 97 💬 |
743 |
Iron sulphate 200mg coated tablets |
Iron |
- |
- |
- |
096 2件: 96, 97 💬 |
744 |
Iron(iii)- hydroxide dextran complex |
Dextran |
1件: D00060 D00060 💬 |
- |
- |
096 2件: 96, 97 💬 |
745 |
Isotonic sodium chloride solution |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
034 1件: 34 💬 |
746 |
Iv corticosteroid |
- |
- |
- |
- |
097 1件: 97 💬 |
747 |
Jinarc - 15 mg +45 mg - compressa - uso orale - blister(alu/pvc) in confezione a portafoglio - 56 compresse (28x15 mg + 28 x 45 mg) |
- |
- |
- |
- |
067 1件: 67 💬 |
748 |
Jinarc - 15 mg - compressa - uso orale - blister (alu/pvc) - 28 compresse |
- |
- |
- |
- |
067 1件: 67 💬 |
749 |
Jinarc - 30 mg + 60 mg - compressa - uso orale - blister(alu/pvc) in confezione a portafoglio - 56 compresse (28 x 30 mg + 28 x 60 mg) |
- |
- |
- |
- |
067 1件: 67 💬 |
750 |
Jinarc - 30 mg +90 mg - compressa - uso orale - blister(alu/pvc) in confezione a portafoglio - 56 compresse (28 x 30 mg + 28 x 90 mg) |
- |
- |
- |
- |
067 1件: 67 💬 |
751 |
Jinarc - 30 mg - compressa - uso orale - blister (alu/pvc) - 28 compresse |
- |
- |
- |
- |
067 1件: 67 💬 |
752 |
Jnj-38518168-zbq - film-coated tablet - 10 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
753 |
Jnj-38518168-zbq - film-coated tablet - 10mg |
- |
- |
- |
- |
046 1件: 46 💬 |
754 |
Jnj-38518168-zbq - film-coated tablet - 3 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
755 |
Jnj-38518168-zbq - film-coated tablet - 30 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
756 |
Jnj-38518168-zbq - film-coated tablet - 30mg |
- |
- |
- |
- |
046 1件: 46 💬 |
757 |
Jnj-38518168-zbq - film-coated tablet - 3mg |
- |
- |
- |
- |
046 1件: 46 💬 |
758 |
Jnj-39758979-aac - enteric coated tablet - 10 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
759 |
Jnj-39758979-aac - enteric coated tablet - 100 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
760 |
Jnj-39758979-aac - enteric coated tablet - 30 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
761 |
Kalydeco 150 mg film-coated tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
762 |
Kvd900 100 mg film coated tablet |
- |
- |
- |
- |
065 1件: 65 💬 |
763 |
L01x co2 |
- |
- |
- |
- |
046 1件: 46 💬 |
764 |
L04aa04 - immunoglobulina antitimocitaria (di coniglio) immunoglobulina di coniglio antitimociti umani thymoglobuline |
Antithymocyte immunoglobulin (rabbit) |
- |
- |
- |
013 1件: 13 💬 |
765 |
Lactose in water |
Lactose |
3件: D00001 D00001, D00046 D00046, D03226 D03226 💬 |
- |
- |
097 1件: 97 💬 |
766 |
Lap tap bupivacaine/epinephrine |
Bupivacaine |
5件: D00095 D00095, D00996 D00996, D01450 D01450, D02149 D02149, D07552 D07552 💬 |
ADRA1A 14件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
AMPK signaling pathway 15件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
096 1件: 96 💬 |
767 |
Lentiviral vector containing abca4 gene |
- |
- |
- |
- |
301 1件: 301 💬 |
768 |
Lentiviral vector containing myo7a gene |
- |
- |
- |
- |
090 2件: 90, 303 💬 |
769 |
Lentiviral vector containing the human my07a gene |
- |
- |
- |
- |
090 2件: 90, 303 💬 |
770 |
Levodopa cr (controlled release) |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
771 |
Levodopa, carbidopa, entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
772 |
Levodopa, decarboxylase inhibitor and comt inhibitor |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
773 |
Levodopa-carbidopa-entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
774 |
Levodopa/carbidopa/entacapone |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
775 |
Lidocaine |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 10件: 6 , 13, 34, 46, 51, 86, 168, 226, 231, 256 💬 |
776 |
Lidocaine 1% injectable solution |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
034 1件: 34 💬 |
777 |
Lidocaine 2% without vessel constrictor |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
051 1件: 51 💬 |
778 |
Lidocaine injection 2% |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
168 1件: 168 💬 |
779 |
Lidocaine patch 5% |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
013 1件: 13 💬 |
780 |
Lidocaine releasing intravesical system - liris® |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
226 1件: 226 💬 |
781 |
Linaclotide |
Linaclotide |
1件: D09355 D09355 💬 |
GUCY2C 1件: GUCY2C 💬 |
Metabolic pathways 2件: Metabolic pathways, Purine metabolism |
097 1件: 97 💬 |
782 |
Lipasa ácida lisosómica, esterasa, colesterol (gen humano lipa), lipasa ácida lisosómica (gen humano lipa) |
- |
- |
- |
- |
019 1件: 19 💬 |
783 |
Lisinopril, losartan, and atorvastatin |
Atorvastatin |
7件: D00258 D00258, D00357 D00357, D00362 D00362, D00887 D00887, D07474 D07474, D08131 D08131, D08146 D08146 💬 |
ACE 3件: ACE, AGTR1, HMGCR 💬 |
AGE-RAGE signaling pathway in diabetic complications 22件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Bile secretion, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Terpenoid backbone biosynthesis, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
222 1件: 222 💬 |
784 |
Lo-ovral oral contraceptive pills |
- |
- |
- |
- |
060 1件: 60 💬 |
785 |
Local anesthesia (lidocaine hydrochloride) |
Lidocaine |
3件: D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 1件: 6 💬 |
786 |
Locally approved intravenous contrast medium for contrast enhanced mri |
- |
- |
- |
- |
013 1件: 13 💬 |
787 |
Lodotra (delayed release prednisolone) |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
041 1件: 41 💬 |
788 |
Long-circulating liposomal prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
789 |
Losartan |
Losartan |
2件: D00357 D00357, D08146 D08146 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
017 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬 |
790 |
Losartan and atenolol or propranolol |
Atenolol |
5件: D00235 D00235, D00357 D00357, D00483 D00483, D08146 D08146, D08443 D08443 💬 |
ADRB1 4件: ADRB1, ADRB2, ADRB3, AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 22件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
167 1件: 167 💬 |
791 |
Losartan and nebivolol |
Losartan |
3件: D00357 D00357, D05127 D05127, D08146 D08146 💬 |
ADRB1 2件: ADRB1, AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 21件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
167 1件: 167 💬 |
792 |
Losartan and other angiotensin receptor blockers |
Angiotensin II |
4件: D00150 D00150, D00357 D00357, D02014 D02014, D08146 D08146 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 1件: 19 💬 |
793 |
Losartan bluefish 50 mg |
Bluefish |
2件: D00357 D00357, D08146 D08146 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
058 1件: 58 💬 |
794 |
Losartan hexal |
Losartan |
2件: D00357 D00357, D08146 D08146 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
036 1件: 36 💬 |
795 |
Losartan potasico |
Losartan |
2件: D00357 D00357, D08146 D08146 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
179 1件: 179 💬 |
796 |
Losartan potassium |
Losartan |
3件: D00357 D00357, D08146 D08146, D08403 D08403 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
036 5件: 36, 98, 167, 179, 215 💬 |
797 |
Losartan tablets & qingremoshen granule |
Losartan |
2件: D00357 D00357, D08146 D08146 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
222 1件: 222 💬 |
798 |
Low antigen content diet |
- |
- |
- |
- |
066 1件: 66 💬 |
799 |
Low dose prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
084 1件: 84 💬 |
800 |
Low dose vehicle control |
- |
- |
- |
- |
046 1件: 46 💬 |
801 |
Lum/iva fixed-dose combination |
- |
- |
- |
- |
299 1件: 299 💬 |
802 |
Lumacaftor plus ivacaftor combination |
Ivacaftor |
2件: D09916 D09916, D10134 D10134 💬 |
CFTR 1件: CFTR 💬 |
ABC transporters 8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
299 1件: 299 💬 |
803 |
Lumacaftor, ivacaftor drug combination |
Ivacaftor |
2件: D09916 D09916, D10134 D10134 💬 |
CFTR 1件: CFTR 💬 |
ABC transporters 8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
299 1件: 299 💬 |
804 |
Lzrse-col7a1 engineered autologous epidermal sheets |
- |
- |
- |
- |
036 1件: 36 💬 |
805 |
Mabcampath 10 mg/ml concentrado para solución para perfusión |
- |
- |
- |
- |
013 1件: 13 💬 |
806 |
Mabthera 100 mg concentrate for solution for infusion |
- |
- |
- |
- |
222 1件: 222 💬 |
807 |
Mabthera 500 mg (10 mg/ml) concentrate for solution for infusion |
- |
- |
- |
- |
046 1件: 46 💬 |
808 |
Mabthera 500 mg concentrado para solución para perfusión |
- |
- |
- |
- |
046 1件: 46 💬 |
809 |
Mabthera 500 mg concentrate for solution for infusion |
- |
- |
- |
- |
046 2件: 46, 222 💬 |
810 |
Mabthera®, 100 mg concentrado para solución para perfusión |
- |
- |
- |
- |
046 1件: 46 💬 |
811 |
Mabthera®, 100 mg concentrate for solution for infusion |
- |
- |
- |
- |
046 1件: 46 💬 |
812 |
Magnesium sulfate |
Magnesium |
1件: D01108 D01108 💬 |
- |
- |
011 3件: 11, 296, 297 💬 |
813 |
Marketed plasma-derived vwf/fviii concentrate |
- |
- |
- |
- |
288 1件: 288 💬 |
814 |
Medical air vs oxygen |
Medical air |
1件: D00003 D00003 💬 |
- |
- |
193 1件: 193 💬 |
815 |
Medical grade oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
816 |
Medium dose prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
084 1件: 84 💬 |
817 |
Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) |
- |
- |
- |
- |
013 1件: 13 💬 |
818 |
Mesalazine with hydrocortisone sodium succinate |
Hydrocortisone |
2件: D00088 D00088, D00377 D00377 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
819 |
Metabolic cofactor supplementation |
- |
- |
- |
- |
006 1件: 6 💬 |
820 |
Metformina - 500 30 compresse 500 mg |
Metformin |
2件: D00944 D00944, D04966 D04966 💬 |
PRKAA1 2件: PRKAA1, PRKAA2 💬 |
AMPK signaling pathway 19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
113 1件: 113 💬 |
821 |
Methotrexate - etanercept - prednisolone arm |
Etanercept |
11件: D00142 D00142, D00472 D00472, D00742 D00742, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02115 D02115, D02156 D02156, D03301 D03301 💬 |
DHFR 5件: DHFR, DHFR2, LTA, NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 70件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
822 |
Methyl prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
043 3件: 43, 49, 96 💬 |
823 |
Methylphenidate |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 7件: 6 , 13, 34, 84, 113, 179, 206 💬 |
824 |
Methylphenidate (mpd) |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 1件: 6 💬 |
825 |
Methylphenidate (overencapsulated) |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
826 |
Methylphenidate 10mg tablets |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
827 |
Methylphenidate hydrochloride |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 2件: 6 , 13 💬 |
828 |
Methylphenidate modified release |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
829 |
Methylphenidate modified release 20 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
830 |
Methylphenidate modified release 30 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
831 |
Methylphenidate modified release 40 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
832 |
Methylphenidate, fluoxetin, risperidone |
Fluoxetine |
5件: D00326 D00326, D00426 D00426, D00823 D00823, D01296 D01296, D04999 D04999 💬 |
DRD2 5件: DRD2, HTR2A, SLC6A2, SLC6A3, SLC6A4 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Serotonergic synapse, Synaptic vesicle cycle, cAMP signaling pathway |
179 2件: 179, 206 💬 |
833 |
Methylprednisolone or prednisolone |
Methylprednisolone |
14件: D00407 D00407, D00472 D00472, D00751 D00751, D00979 D00979, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
065 1件: 65 💬 |
834 |
Metoclopramide accord - 10 mg compresse 28 compresse in blister pvc/pvdc/al |
Metoclopramide |
3件: D00726 D00726, D02213 D02213, D05008 D05008 💬 |
DRD2 1件: DRD2 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
051 1件: 51 💬 |
835 |
Metopirone 250 mg capsules/cormeto |
- |
- |
- |
- |
075 1件: 75 💬 |
836 |
Metotrexato sandoz - 2.5 mg compresse 50 compresse in flacone pp |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
837 |
Metotrexato-lederle 2,5 mg comprimidos |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
838 |
Microgynon® 30 (oral contraceptive) |
- |
- |
- |
- |
046 1件: 46 💬 |
839 |
Minocycline 100 mg film-coated tablets |
Minocycline |
2件: D00850 D00850, D05045 D05045 💬 |
- |
- |
013 1件: 13 💬 |
840 |
Modified cobratoxin |
- |
- |
- |
- |
020 1件: 20 💬 |
841 |
Morphine |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
036 5件: 36, 46, 70, 85, 86 💬 |
842 |
Morphine hexal |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
843 |
Morphine hydrochloride |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
085 1件: 85 💬 |
844 |
Morphine pca |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
070 1件: 70 💬 |
845 |
Morphine sulfate |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 3件: 46, 85, 86 💬 |
846 |
Morphine sulphate in intrasite gel |
Morphine |
3件: D00842 D00842, D02271 D02271, D08233 D08233 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
036 1件: 36 💬 |
847 |
Myeloablative conditioning regimen |
- |
- |
- |
- |
164 1件: 164 💬 |
848 |
Myeloablative conditioning-closed with amendment l |
- |
- |
- |
- |
065 1件: 65 💬 |
849 |
Myozyme 50 mg powder for concentrate for solution for infusion |
- |
- |
- |
- |
256 1件: 256 💬 |
850 |
Méthotrexate bellon comprimé |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
271 1件: 271 💬 |
851 |
Nebulized combination ipratropium bromide with salbutamol |
Ipratropium |
2件: D02147 D02147, D02212 D02212 💬 |
ADRB2 6件: ADRB2, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Adrenergic signaling in cardiomyocytes 17件: Adrenergic signaling in cardiomyocytes, Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
852 |
Neoral soft gelatin capsules |
Gelatin |
2件: D00115 D00115, D06892 D06892 💬 |
- |
- |
097 2件: 97, 269 💬 |
853 |
Nerixia*infus iv conc 2f 100mg |
- |
- |
- |
- |
274 1件: 274 💬 |
854 |
Nifurtimox-eflronithine combination treatment (nect) |
Nifurtimox |
1件: D00833 D00833 💬 |
- |
- |
065 1件: 65 💬 |
855 |
Nitisinone 10 mg tablet high compritol |
Nitisinone |
1件: D05177 D05177 💬 |
HPD 1件: HPD 💬 |
Biosynthesis of cofactors 5件: Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis |
241 1件: 241 💬 |
856 |
Nitric oxide plus oxygen |
Nitric Oxide |
2件: D00003 D00003, D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
857 |
Non atg conditioning regimen |
- |
- |
- |
- |
060 1件: 60 💬 |
858 |
Norvir 100 mg film-coated tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
859 |
Novartis pharmaceuticals corporation |
- |
- |
- |
- |
013 1件: 13 💬 |
860 |
Nutraceutical combination |
- |
- |
- |
- |
096 1件: 96 💬 |
861 |
Nutritional formulation containing exogenous ketones |
- |
- |
- |
- |
201 1件: 201 💬 |
862 |
Ondansetron 8 mg film-coated tablets |
Ondansetron |
2件: D00456 D00456, D00678 D00678 💬 |
HTR3A 5件: HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Taste transduction |
006 1件: 6 💬 |
863 |
Optivate® (human coagulation factor viii) |
Antihemophilic factor human |
- |
- |
- |
288 1件: 288 💬 |
864 |
Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone |
Mesalazine |
7件: D00377 D00377, D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
865 |
Oral bovine type i collagen |
Bovine type I collagen |
- |
- |
- |
051 1件: 51 💬 |
866 |
Oral bovine type ii collagen |
- |
- |
- |
- |
046 1件: 46 💬 |
867 |
Oral ciprofloxacin plus inhaled colistin |
Ciprofloxacin |
4件: D00186 D00186, D02138 D02138, D02216 D02216, D07746 D07746 💬 |
- |
- |
299 1件: 299 💬 |
868 |
Oral corticosteroids |
- |
- |
- |
- |
013 3件: 13, 46, 97 💬 |
869 |
Oral corticosteroids (ocs) |
- |
- |
- |
- |
162 1件: 162 💬 |
870 |
Oral prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
049 2件: 49, 145 💬 |
871 |
Orencia 250 mg polvo para concentrado para sol. para perfusión |
- |
- |
- |
- |
046 1件: 46 💬 |
872 |
Orencia 250mg powder for concentrate for solution for infusion |
- |
- |
- |
- |
046 1件: 46 💬 |
873 |
Orkambi 100 mg/125 mg film-coated tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
874 |
Orkambi 200 mg/125 mg film-coated tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
875 |
Orkambi: contains lumacaftor and ivacaftor |
Ivacaftor |
2件: D09916 D09916, D10134 D10134 💬 |
CFTR 1件: CFTR 💬 |
ABC transporters 8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
299 1件: 299 💬 |
876 |
Other cox-2 inhibitor |
- |
- |
- |
- |
271 1件: 271 💬 |
877 |
Other cox-2 inhibitors |
- |
- |
- |
- |
271 1件: 271 💬 |
878 |
Other: 0.9% sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
065 1件: 65 💬 |
879 |
Other: 0.9ml sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
271 1件: 271 💬 |
880 |
Other: 60% oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
085 1件: 85 💬 |
881 |
Other: abdominal compression |
- |
- |
- |
- |
017 1件: 17 💬 |
882 |
Other: ad libitum water intake |
Water |
1件: D00001 D00001 💬 |
- |
- |
067 1件: 67 💬 |
883 |
Other: air - oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
884 |
Other: assessment of medication compliance |
- |
- |
- |
- |
098 1件: 98 💬 |
885 |
Other: blood collection for measurement of eculizumab peak concentrations |
Eculizumab |
1件: D03940 D03940 💬 |
C5 1件: C5 💬 |
Complement and coagulation cascades 9件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 1件: 62 💬 |
886 |
Other: blood sample and cotton skin swabs |
Cotton |
- |
- |
- |
162 1件: 162 💬 |
887 |
Other: bmi greater than or equal to 30kg/m2 scheduled for psg. undergo blood draw (arterial blood gas and metabolic panel) and data collection from psg study. |
- |
- |
- |
- |
230 1件: 230 💬 |
888 |
Other: bmi greater than or equal to 30kg/m2 scheduled for psg. undergo blood draw (venous blood gas and metabolic panel) and data collection from psg study. |
- |
- |
- |
- |
230 1件: 230 💬 |
889 |
Other: cawthorne cooksey exercises |
- |
- |
- |
- |
013 1件: 13 💬 |
890 |
Other: coa-z |
- |
- |
- |
- |
120 1件: 120 💬 |
891 |
Other: coaching sessions |
- |
- |
- |
- |
049 1件: 49 💬 |
892 |
Other: coduse balance training and step square exercises |
Isoxaflutole |
- |
- |
- |
013 1件: 13 💬 |
893 |
Other: coffee |
- |
- |
- |
- |
096 1件: 96 💬 |
894 |
Other: cognitive training |
- |
- |
- |
- |
206 1件: 206 💬 |
895 |
Other: colchicine cessation |
Colchicine |
1件: D00570 D00570 💬 |
TUBB 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 |
Alzheimer disease 10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection |
266 1件: 266 💬 |
896 |
Other: collection of csf, blood, urine, saliva |
- |
- |
- |
- |
006 1件: 6 💬 |
897 |
Other: communicative effectiveness survey |
- |
- |
- |
- |
002 1件: 2 💬 |
898 |
Other: comparator: cpet cycle ergometer (gold standard) |
Gold |
- |
- |
- |
299 1件: 299 💬 |
899 |
Other: computer game based balance and walking rehabilitation for individuals with parkinson's disease |
Isoxaflutole |
- |
- |
- |
006 1件: 6 💬 |
900 |
Other: concomitant medication |
- |
- |
- |
- |
049 1件: 49 💬 |
901 |
Other: continuation of dornase alfa (dnase) |
Dornase alfa |
1件: D03896 D03896 💬 |
- |
- |
299 1件: 299 💬 |
902 |
Other: continuation of hypertonic saline (hs) |
- |
- |
- |
- |
299 1件: 299 💬 |
903 |
Other: continue their usual therapy |
- |
- |
- |
- |
066 1件: 66 💬 |
904 |
Other: control |
- |
- |
- |
- |
006 8件: 6 , 19, 70, 75, 85, 97, 162, 193 💬 |
905 |
Other: control diet |
- |
- |
- |
- |
096 1件: 96 💬 |
906 |
Other: control group |
- |
- |
- |
- |
002 1件: 2 💬 |
907 |
Other: control group(normal saline) |
- |
- |
- |
- |
097 1件: 97 💬 |
908 |
Other: control wound treatment |
- |
- |
- |
- |
036 1件: 36 💬 |
909 |
Other: controlled environment tests (series of tasks of everyday life) |
- |
- |
- |
- |
006 1件: 6 💬 |
910 |
Other: controls primary cervical dystonia (trihexyphenidyl) |
Trihexyphenidyl |
2件: D00787 D00787, D08638 D08638 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 1件: 6 💬 |
911 |
Other: conventional balance training |
Isoxaflutole |
- |
- |
- |
013 1件: 13 💬 |
912 |
Other: conventional drugs |
- |
- |
- |
- |
097 1件: 97 💬 |
913 |
Other: conventional pca mode |
- |
- |
- |
- |
070 1件: 70 💬 |
914 |
Other: core stability |
- |
- |
- |
- |
013 1件: 13 💬 |
915 |
Other: corn starch |
Starch, corn |
1件: D05297 D05297 💬 |
- |
- |
049 1件: 49 💬 |
916 |
Other: corticotropin releasing hormone (crh) |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
078 1件: 78 💬 |
917 |
Other: cough monitor |
Methamidophos |
- |
- |
- |
085 1件: 85 💬 |
918 |
Other: dead sea solar and water treatment |
Water |
1件: D00001 D00001 💬 |
- |
- |
046 1件: 46 💬 |
919 |
Other: dextrose water 5% |
Dextrose, unspecified form |
1件: D00001 D00001 💬 |
- |
- |
056 1件: 56 💬 |
920 |
Other: diary completion |
- |
- |
- |
- |
006 1件: 6 💬 |
921 |
Other: dyt 1 dystonia (healthy control) |
- |
- |
- |
- |
006 1件: 6 💬 |
922 |
Other: exercise followed cold water immersion |
Water |
1件: D00001 D00001 💬 |
- |
- |
046 1件: 46 💬 |
923 |
Other: group exercise: community setting |
- |
- |
- |
- |
070 1件: 70 💬 |
924 |
Other: harkány medicinal water |
Water |
1件: D00001 D00001 💬 |
- |
- |
046 1件: 46 💬 |
925 |
Other: healthy controls |
- |
- |
- |
- |
063 1件: 63 💬 |
926 |
Other: high resolution peripheral quantitative computed tomography (hrpqct) |
- |
- |
- |
- |
172 1件: 172 💬 |
927 |
Other: high water intake |
Water |
1件: D00001 D00001 💬 |
- |
- |
067 1件: 67 💬 |
928 |
Other: histamine |
Histamine |
1件: D08040 D08040 💬 |
HRH1 4件: HRH1, HRH2, HRH3, HRH4 💬 |
Calcium signaling pathway 4件: Calcium signaling pathway, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
013 1件: 13 💬 |
929 |
Other: historical control |
- |
- |
- |
- |
002 1件: 2 💬 |
930 |
Other: human umbilical cord-derived mscs and cyclosporin a |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
060 1件: 60 💬 |
931 |
Other: hydrocortisone |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
075 1件: 75 💬 |
932 |
Other: hyperbaric oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
096 1件: 96 💬 |
933 |
Other: hyperbaric oxygen therapy |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
097 2件: 97, 226 💬 |
934 |
Other: ibuprofen and isosorbide dinitrate combination |
Ibuprofen |
6件: D00126 D00126, D00347 D00347, D00516 D00516, D01122 D01122, D04490 D04490, D06606 D06606 💬 |
PTGS1 2件: PTGS1, PTGS2 💬 |
Alzheimer disease 23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
113 1件: 113 💬 |
935 |
Other: impact of biotherapy on postoperative morbidity in ulcerative colitis |
- |
- |
- |
- |
097 1件: 97 💬 |
936 |
Other: iv steroids combination alone |
- |
- |
- |
- |
041 1件: 41 💬 |
937 |
Other: leukapheresis- collection of stem cells |
- |
- |
- |
- |
096 1件: 96 💬 |
938 |
Other: losartan |
Losartan |
2件: D00357 D00357, D08146 D08146 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
046 1件: 46 💬 |
939 |
Other: low blood pressure control |
- |
- |
- |
- |
067 1件: 67 💬 |
940 |
Other: medication compliance phone call |
- |
- |
- |
- |
098 1件: 98 💬 |
941 |
Other: natural herbs of coconut, aloe vera, and pepperint |
Aloe Vera Leaf |
- |
- |
- |
053 1件: 53 💬 |
942 |
Other: no msdmds therapy (control) |
- |
- |
- |
- |
013 1件: 13 💬 |
943 |
Other: normal (control) diet |
- |
- |
- |
- |
240 1件: 240 💬 |
944 |
Other: nutrition counseling |
- |
- |
- |
- |
298 1件: 298 💬 |
945 |
Other: observational cohort |
- |
- |
- |
- |
006 1件: 6 💬 |
946 |
Other: observational control |
- |
- |
- |
- |
013 1件: 13 💬 |
947 |
Other: optional blood-oxygen-level dependent functionalmri |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
006 1件: 6 💬 |
948 |
Other: oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
085 1件: 85 💬 |
949 |
Other: oxygen (2liter/min) |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
085 1件: 85 💬 |
950 |
Other: oxygen (4liter/min) |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
085 1件: 85 💬 |
951 |
Other: oxygen - air |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
952 |
Other: oxygen supplementation |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
086 1件: 86 💬 |
953 |
Other: pittsburgh compound b [11c]-pib |
Pittsburgh Compound B |
- |
- |
- |
006 1件: 6 💬 |
954 |
Other: plasticity-based computerized cognitive remediation program |
- |
- |
- |
- |
013 1件: 13 💬 |
955 |
Other: potable water |
Water |
1件: D00001 D00001 💬 |
- |
- |
019 1件: 19 💬 |
956 |
Other: reaction time and postural control |
- |
- |
- |
- |
299 1件: 299 💬 |
957 |
Other: serum calcium concentrations results |
Calcium |
- |
- |
- |
235 1件: 235 💬 |
958 |
Other: sham abdominal compression |
- |
- |
- |
- |
017 1件: 17 💬 |
959 |
Other: sham comparator |
- |
- |
- |
- |
299 1件: 299 💬 |
960 |
Other: sham-procedure (dose cohort 1&2 only) |
- |
- |
- |
- |
090 2件: 90, 303 💬 |
961 |
Other: sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
051 1件: 51 💬 |
962 |
Other: standard blood pressure control |
- |
- |
- |
- |
067 1件: 67 💬 |
963 |
Other: technetium [tc-99m] sulfur colloid and indium [in-111] dtpa |
Indium |
1件: D05422 D05422 💬 |
- |
- |
299 1件: 299 💬 |
964 |
Other: the patients' parents have to complete the vineland ii adaptive behavior scales scoring, the sleep disturbance scale for children (sdsc) and horne & ostberg circadian typology questionnaire |
- |
- |
- |
- |
149 1件: 149 💬 |
965 |
Other: ulcerative colitis diet |
- |
- |
- |
- |
097 1件: 97 💬 |
966 |
Other: untreated cohort |
- |
- |
- |
- |
085 1件: 85 💬 |
967 |
Other: voluntary cough test |
- |
- |
- |
- |
006 1件: 6 💬 |
968 |
Other: water |
Water |
1件: D00001 D00001 💬 |
- |
- |
067 1件: 67 💬 |
969 |
Other: water prescription |
Water |
1件: D00001 D00001 💬 |
- |
- |
067 1件: 67 💬 |
970 |
Over the counter dha/epa dietary supplementation |
- |
- |
- |
- |
301 1件: 301 💬 |
971 |
Over-encapsulated entacapone tablets |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
972 |
Overencapsulated prednisolone tablets |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
973 |
Ovine corticotropin-releasing hormone (ocrh) |
Corticorelin |
2件: D00146 D00146, D03905 D03905 💬 |
CRHR1 3件: CRHR1, CRHR2, MC2R 💬 |
Aldosterone synthesis and secretion 6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
075 1件: 75 💬 |
974 |
Oxycodone by patient-controlled analgesia (pca) |
Oxycodone |
3件: D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
046 1件: 46 💬 |
975 |
Oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
006 18件: 6 , 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 294, 299, 330 💬 |
976 |
Oxygen 40 % |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
085 1件: 85 💬 |
977 |
Oxygen supplementation |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
086 1件: 86 💬 |
978 |
Oxygen, liquid |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
086 2件: 86, 88 💬 |
979 |
Oxytocin (oxt) continuous |
Oxytocin |
1件: D00089 D00089 💬 |
OXTR 1件: OXTR 💬 |
Calcium signaling pathway 4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
193 1件: 193 💬 |
980 |
Pancrecarb® (pancrelipase) |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
299 1件: 299 💬 |
981 |
Pancrelipase |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
298 2件: 298, 299 💬 |
982 |
Pancrelipase amylase |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
299 1件: 299 💬 |
983 |
Pancrelipase delayed release |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
299 1件: 299 💬 |
984 |
Pancrelipase delayed release capsule |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
298 2件: 298, 299 💬 |
985 |
Pancrelipase microtablets |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
299 1件: 299 💬 |
986 |
Pancrelipase with bicarbonate |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
299 1件: 299 💬 |
987 |
Pancrelipase/pancreas powder |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
298 2件: 298, 299 💬 |
988 |
Paroxetine & prednisolone |
Paroxetine |
12件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 2件: NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 1件: 46 💬 |
989 |
Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp |
Paroxetine |
12件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 2件: NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 1件: 46 💬 |
990 |
Paroxetine hydrochloride tablets 10 & 20 mg and prednisolone 1 mg bp |
Paroxetine |
12件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 2件: NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 1件: 46 💬 |
991 |
Part 1, jm-010 component group a |
- |
- |
- |
- |
006 1件: 6 💬 |
992 |
Part 1, jm-010 component group b |
- |
- |
- |
- |
006 1件: 6 💬 |
993 |
Part 1, jm-010 component group c |
- |
- |
- |
- |
006 1件: 6 💬 |
994 |
Part 2, jm-010 combination group a |
- |
- |
- |
- |
006 1件: 6 💬 |
995 |
Part 2, jm-010 combination group b |
- |
- |
- |
- |
006 1件: 6 💬 |
996 |
Part 2, jm-010 component group c |
- |
- |
- |
- |
006 1件: 6 💬 |
997 |
Pct (purecell technologies complex) |
- |
- |
- |
- |
097 1件: 97 💬 |
998 |
Peg-liposomal prednisolone sodium phosphate |
Phosphate ion |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
013 2件: 13, 97 💬 |
999 |
Pentasa compact 2g, granulate with prolonged release |
- |
- |
- |
- |
097 1件: 97 💬 |
1000 |
Pentasa compact 4g, granulate with prolonged release |
- |
- |
- |
- |
097 1件: 97 💬 |
1001 |
Peptide-conjugated phosphorodiamidate morpholino oligomer for exon 51 skipping |
- |
- |
- |
- |
113 1件: 113 💬 |
1002 |
Perfluorinated gas/oxygen mixture |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
1003 |
Ph-combination therapy |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
1004 |
Phase 1: conventiaonal dmard |
- |
- |
- |
- |
046 1件: 46 💬 |
1005 |
Physiological serum (sodium chloride) |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
193 1件: 193 💬 |
1006 |
Piperacillin-tazobactam combination product |
Piperacillin |
4件: D00466 D00466, D00660 D00660, D02251 D02251, D08380 D08380 💬 |
- |
- |
299 1件: 299 💬 |
1007 |
Pittsburgh compound b |
Pittsburgh Compound B |
- |
- |
- |
006 2件: 6 , 127 💬 |
1008 |
Pittsburgh compound b (c-11 pib) |
Pittsburgh Compound B |
- |
- |
- |
127 1件: 127 💬 |
1009 |
Pl 12185/0002 & pl 12185/0005(water for injection) |
Water |
1件: D00001 D00001 💬 |
- |
- |
057 1件: 57 💬 |
1010 |
Placental mesenchymal stem cells seeded on a commercially available dural graft extracellular matrix |
Placental Mesenchymal Stem Cells |
- |
- |
- |
118 1件: 118 💬 |
1011 |
Plaquenil - hydroxychloroquine 200mg film coated tablets |
Hydroxychloroquine |
1件: D08050 D08050 💬 |
- |
- |
043 3件: 43, 44, 45 💬 |
1012 |
Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología prgf-system (bti) |
- |
- |
- |
- |
096 1件: 96 💬 |
1013 |
Plasma-derived fviii/vwf concentrate |
- |
- |
- |
- |
288 1件: 288 💬 |
1014 |
Plerixafor for conditioning before hsct. |
Plerixafor |
1件: D08971 D08971 💬 |
CXCR4 1件: CXCR4 💬 |
Axon guidance 12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
065 1件: 65 💬 |
1015 |
Pneumococcal conjugate vaccine |
- |
- |
- |
- |
046 1件: 46 💬 |
1016 |
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) conjugated to crm197 carrier protein and adsorbed on aluminium phosphate |
Aluminium |
- |
- |
- |
046 1件: 46 💬 |
1017 |
Prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
011 40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 |
1018 |
Prednisolone & dipyridamole |
Dipyridamole |
9件: D00302 D00302, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 3件: NR3C1, PDE4A, PDE5A 💬 |
Metabolic pathways 7件: Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 1件: 46 💬 |
1019 |
Prednisolone + mabthera |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
061 1件: 61 💬 |
1020 |
Prednisolone 1mg tablets |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
1021 |
Prednisolone 2,5 mg tablets |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
1022 |
Prednisolone 20 mg |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1023 |
Prednisolone 40 mg |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1024 |
Prednisolone 5 mg |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 2件: 46, 51 💬 |
1025 |
Prednisolone 5 mg jenapharm |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
041 1件: 41 💬 |
1026 |
Prednisolone 5 mg tablets |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
1027 |
Prednisolone 5mg gastro-resistant tablets |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
051 1件: 51 💬 |
1028 |
Prednisolone 5mg tablet |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
1029 |
Prednisolone acetate |
Acetate |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
222 1件: 222 💬 |
1030 |
Prednisolone and chlorambucil |
Chlorambucil |
9件: D00266 D00266, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
222 1件: 222 💬 |
1031 |
Prednisolone and mycophenolate mofetil |
Mycophenolate mofetil |
12件: D00472 D00472, D00752 D00752, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 3件: IMPDH1, IMPDH2, NR3C1 💬 |
Drug metabolism - other enzymes 4件: Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism |
222 1件: 222 💬 |
1032 |
Prednisolone and taper |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
051 1件: 51 💬 |
1033 |
Prednisolone labesfal |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1034 |
Prednisolone sodium metasulphobenzoate |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
1035 |
Prednisolone sodium phosphate |
Phosphate ion |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
013 2件: 13, 97 💬 |
1036 |
Prednisolone sodium succinate |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
095 1件: 95 💬 |
1037 |
Prednisolone tablets b.p. 5mg |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
097 1件: 97 💬 |
1038 |
Prednisolone tablets bp |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1039 |
Prednisolone tablets bp 1 mg |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1040 |
Prednisolone tablets usp 5 mg |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1041 |
Prednisolone-dipyridamole |
Dipyridamole |
9件: D00302 D00302, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 3件: NR3C1, PDE4A, PDE5A 💬 |
Metabolic pathways 7件: Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 1件: 46 💬 |
1042 |
Prednisolone/prednisone |
Prednisolone |
9件: D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
049 1件: 49 💬 |
1043 |
Prednisone + inhibace/cozaar |
Prednisone |
1件: D00473 D00473 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
066 1件: 66 💬 |
1044 |
Prednisone or prednisolone |
Prednisolone |
9件: D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
066 1件: 66 💬 |
1045 |
Prednisone/prednisolone |
Prednisolone |
9件: D00472 D00472, D00473 D00473, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
035 1件: 35 💬 |
1046 |
Probiotic capsules containing lactobacillus rhamnosus gr-1 and l. reuteri rc-14 |
- |
- |
- |
- |
046 1件: 46 💬 |
1047 |
Procedure: 2 ml of whole blood sample will be collected on edta tube |
Edetic acid |
8件: D00052 D00052, D00571 D00571, D01802 D01802, D03943 D03943, D03944 D03944, D03945 D03945, D03946 D03946, D03947 D03947 💬 |
- |
- |
051 1件: 51 💬 |
1048 |
Procedure: 9% sodium chloride (nacl) iv |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
078 1件: 78 💬 |
1049 |
Procedure: assessment of therapy complications |
- |
- |
- |
- |
060 1件: 60 💬 |
1050 |
Procedure: biospecimen collection |
- |
- |
- |
- |
159 1件: 159 💬 |
1051 |
Procedure: blood collection for pk testing (15 mins before injection) |
- |
- |
- |
- |
046 1件: 46 💬 |
1052 |
Procedure: blood collection for pk testing (15 minutes post injection) |
- |
- |
- |
- |
046 1件: 46 💬 |
1053 |
Procedure: blood collection for pk testing (18-20 hours post injection) |
- |
- |
- |
- |
046 1件: 46 💬 |
1054 |
Procedure: blood collection for pk testing (180 minutes post injection) |
- |
- |
- |
- |
046 1件: 46 💬 |
1055 |
Procedure: blood collection for pk testing (60 minutes post injection) |
- |
- |
- |
- |
046 1件: 46 💬 |
1056 |
Procedure: blood collection for pk testing (after injection) |
- |
- |
- |
- |
046 1件: 46 💬 |
1057 |
Procedure: blood sampling from umbilical cord |
- |
- |
- |
- |
046 3件: 46, 96, 271 💬 |
1058 |
Procedure: bone marrow or umbilical cord blood (ucg) stem cell transplantation |
- |
- |
- |
- |
036 1件: 36 💬 |
1059 |
Procedure: clobetasol propionate |
Clobetasol |
2件: D01272 D01272, D07715 D07715 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
162 1件: 162 💬 |
1060 |
Procedure: colectomy |
- |
- |
- |
- |
097 1件: 97 💬 |
1061 |
Procedure: collagenase |
Collagenase clostridium histolyticum |
1件: D09596 D09596 💬 |
- |
- |
162 1件: 162 💬 |
1062 |
Procedure: colonoscopy |
- |
- |
- |
- |
097 1件: 97 💬 |
1063 |
Procedure: colorectal biopsies |
- |
- |
- |
- |
097 1件: 97 💬 |
1064 |
Procedure: computed tomography |
- |
- |
- |
- |
034 5件: 34, 40, 46, 49, 96 💬 |
1065 |
Procedure: continuous glucose monitoring system (cgms) |
Dextrose, unspecified form |
- |
- |
- |
299 1件: 299 💬 |
1066 |
Procedure: continuous mononuclear cell collection (cmnc) |
- |
- |
- |
- |
096 1件: 96 💬 |
1067 |
Procedure: contrast sensitivity measurement |
- |
- |
- |
- |
019 1件: 19 💬 |
1068 |
Procedure: control group |
- |
- |
- |
- |
034 1件: 34 💬 |
1069 |
Procedure: conventional surgery |
- |
- |
- |
- |
034 1件: 34 💬 |
1070 |
Procedure: cord blood |
- |
- |
- |
- |
060 1件: 60 💬 |
1071 |
Procedure: cord blood infusion |
- |
- |
- |
- |
060 1件: 60 💬 |
1072 |
Procedure: coronary flow reserve se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
1073 |
Procedure: drug coated balloon (dcb) |
- |
- |
- |
- |
040 1件: 40 💬 |
1074 |
Procedure: dynamic contrast-enhanced magnetic resonance imaging |
- |
- |
- |
- |
013 1件: 13 💬 |
1075 |
Procedure: hydrocortisone withdrawal |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
1076 |
Procedure: hyperbaric oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
097 1件: 97 💬 |
1077 |
Procedure: hyperbaric oxygen therapy |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
090 1件: 90 💬 |
1078 |
Procedure: left ventricular contractile reserve se |
- |
- |
- |
- |
058 3件: 58, 86, 215 💬 |
1079 |
Procedure: long term oxygen therapy |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
088 1件: 88 💬 |
1080 |
Procedure: management of therapy complications |
- |
- |
- |
- |
028 2件: 28, 60 💬 |
1081 |
Procedure: mri imaging with intravenous contrast with gadoterate meglumine |
Gadoteric acid |
2件: D01796 D01796, D08007 D08007 💬 |
- |
- |
053 1件: 53 💬 |
1082 |
Procedure: non-myeloablative high dose immunosuppressive therapy conditioning (hdit) |
- |
- |
- |
- |
049 1件: 49 💬 |
1083 |
Procedure: oxygen flow at the optic nerve head measurement |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
019 1件: 19 💬 |
1084 |
Procedure: single photon emission computed tomography |
- |
- |
- |
- |
034 1件: 34 💬 |
1085 |
Procedure: sputum collection |
- |
- |
- |
- |
299 1件: 299 💬 |
1086 |
Procedure: stem cell collection |
- |
- |
- |
- |
028 1件: 28 💬 |
1087 |
Procedure: stem cell or umbilical cord blood transplantation |
- |
- |
- |
- |
326 1件: 326 💬 |
1088 |
Procedure: supplemental oxygen via a mask |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
088 1件: 88 💬 |
1089 |
Procedure: umbilical cord blood therapy |
Umbilical Cord Blood Hematopoietic Stem Cells |
- |
- |
- |
002 2件: 2 , 6 💬 |
1090 |
Procedure: umbilical cord blood transplantation |
- |
- |
- |
- |
060 5件: 60, 65, 284, 285, 326 💬 |
1091 |
Procedure: urinary collect |
- |
- |
- |
- |
299 1件: 299 💬 |
1092 |
Procedure: urine collection |
- |
- |
- |
- |
019 1件: 19 💬 |
1093 |
Procedure: warm compress prior to injection of glatiramer acetate |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
1094 |
Procedure: water exercises |
Water |
1件: D00001 D00001 💬 |
- |
- |
046 1件: 46 💬 |
1095 |
Products containing aminosalicylate |
- |
- |
- |
- |
097 1件: 97 💬 |
1096 |
Products containing azathioprine or 6-mercaptopurine |
Azathioprine |
4件: D00161 D00161, D00238 D00238, D03033 D03033, D04931 D04931 💬 |
HPRT1 1件: HPRT1 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
097 1件: 97 💬 |
1097 |
Prothrombin complex concentrate |
Factor IX Complex (Human) |
- |
- |
- |
288 1件: 288 💬 |
1098 |
Ps188 (company code) |
- |
- |
- |
- |
113 1件: 113 💬 |
1099 |
Pseudoephedrine + 480 ml water |
Pseudoephedrine |
5件: D00001 D00001, D00485 D00485, D05648 D05648, D05649 D05649, D08449 D08449 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
017 1件: 17 💬 |
1100 |
Pseudoephedrine + 50 ml water |
Pseudoephedrine |
5件: D00001 D00001, D00485 D00485, D05648 D05648, D05649 D05649, D08449 D08449 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
017 1件: 17 💬 |
1101 |
Ptc0161480, ptc124 compound 1a, rps2505, ptc-c124, 291844 |
- |
- |
- |
- |
113 1件: 113 💬 |
1102 |
Pyridoxine plus prednisolone |
Prednisolone |
10件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02179 D02179, D03301 D03301, D08454 D08454 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
145 1件: 145 💬 |
1103 |
Radiation: computed tomography lung subtraction iodine mapping |
Iodine |
1件: D00108 D00108 💬 |
- |
- |
088 1件: 88 💬 |
1104 |
Radiation: computerized tomography scan |
- |
- |
- |
- |
098 1件: 98 💬 |
1105 |
Radiation: cone beam computed tomography (cbct) |
Tricyclazole |
- |
- |
- |
051 1件: 51 💬 |
1106 |
Radiation: single photon emission computed tomography scans |
- |
- |
- |
- |
098 1件: 98 💬 |
1107 |
Rapamune - 1 mg 100 compresse rivestite in blister uso orale |
- |
- |
- |
- |
002 1件: 2 💬 |
1108 |
Rapamycin-calcitriol combination |
Calcitriol |
2件: D00129 D00129, D00753 D00753 💬 |
MTOR 2件: MTOR, VDR 💬 |
AMPK signaling pathway 54件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Mineral absorption, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Tuberculosis, Type II diabetes mellitus, mTOR signaling pathway |
158 1件: 158 💬 |
1109 |
Raxone - 150 mg- compresse rivestite con film- uso orale- flacone (hdpe)- 180 compresse |
- |
- |
- |
- |
113 1件: 113 💬 |
1110 |
Recombinanat dna-derived human growth hormone produced in e.coli |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
1111 |
Recombinant aav vector serotype 2 containing the human wild type mitochondrial nd4 gene |
- |
- |
- |
- |
302 1件: 302 💬 |
1112 |
Recombinant adeno-associated viral vector serotype 2.7m8 containing the chrimsonr-tdtomato gene |
- |
- |
- |
- |
090 1件: 90 💬 |
1113 |
Recombinant adeno-associated viral vector, serotype 2 (raav2/2) containing the human wild-type mitochondrial nadh dehydrogenase 4 gene (nd4) |
NADH |
- |
- |
- |
302 1件: 302 💬 |
1114 |
Recombinant coagulation fviii fc – von willebrand factor – xten fusion protein |
Von Willebrand Factor Human |
- |
- |
- |
288 1件: 288 💬 |
1115 |
Recombinant coagulation fviii fc – vonwillebrand factor – xten fusion protein |
- |
- |
- |
- |
288 1件: 288 💬 |
1116 |
Recombinant dna-derived human growth hormone produced in e.coli |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
1117 |
Recombinant granulocyte - colony stimulating factor |
- |
- |
- |
- |
039 1件: 39 💬 |
1118 |
Recombinant human ?-glucosidase conjugated with synthetic bismannose-6-phosphate-man6 glycan |
Phosphate ion |
- |
- |
- |
256 1件: 256 💬 |
1119 |
Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (neogaa) |
Avalglucosidase alfa |
1件: D11744 D11744 💬 |
GAA 1件: GAA 💬 |
Galactose metabolism 4件: Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
256 1件: 256 💬 |
1120 |
Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan avalglucosidase alfa (neogaa) |
Avalglucosidase alfa |
1件: D11744 D11744 💬 |
GAA 1件: GAA 💬 |
Galactose metabolism 4件: Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism |
256 1件: 256 💬 |
1121 |
Recombinant human angiotensin-converting enzyme 2 |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
1122 |
Recombinant human angiotensin-converting enzyme 2 (ace2), apn01 |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
1123 |
Recombinant human apolipoprotein a-i/phospholipids complex |
Omega-3 fatty acids |
- |
- |
- |
079 1件: 79 💬 |
1124 |
Recombinant human coagulation factor viii fc - von willebrand factor - xten fusion protein |
Antihemophilic factor human |
- |
- |
- |
288 1件: 288 💬 |
1125 |
Recombinant porcine coagulation factor viii (b domain deleted) |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
1126 |
Recombinant porcine coagulation factor viii (b-domain deleted) |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
1127 |
Reduced intensity conditioning |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
1128 |
Reduced intensity conditioning (ric) |
- |
- |
- |
- |
065 1件: 65 💬 |
1129 |
Reduced intensity transplant conditioning |
- |
- |
- |
- |
036 1件: 36 💬 |
1130 |
Regimen selection phase group 1 (completed) |
- |
- |
- |
- |
113 1件: 113 💬 |
1131 |
Remicade 100 mg polvo para concentrado para solución para perfusión |
- |
- |
- |
- |
046 2件: 46, 271 💬 |
1132 |
Remicade 100 mg powder for concentrate for solution for infusion. |
- |
- |
- |
- |
096 2件: 96, 97 💬 |
1133 |
Remsima - 100 mg polvere per concentrato per soluzione per infusione - uso endovenoso - flanconcino (vetro) - 1 flaconcino |
- |
- |
- |
- |
046 4件: 46, 96, 97, 271 💬 |
1134 |
Repository corticotropin injection |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
002 5件: 2 , 13, 46, 84, 222 💬 |
1135 |
Repository corticotropin injection -treatment extension |
Corticotropin |
1件: D00146 D00146 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
084 1件: 84 💬 |
1136 |
Revatio 20 mg film coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
1137 |
Revatio 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
1138 |
Revatio 20 mg, comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
1139 |
Revatio ® 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
1140 |
Revolade 25 mg film-coated tablets |
- |
- |
- |
- |
063 1件: 63 💬 |
1141 |
Revolade 50 mg film-coated tablets |
- |
- |
- |
- |
063 1件: 63 💬 |
1142 |
Rhtpo in combination with rituximab |
Recombinant Human Thrombopoietin |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
063 1件: 63 💬 |
1143 |
Ribavirin |
Ribavirin |
1件: D00423 D00423 💬 |
- |
- |
002 2件: 2 , 96 💬 |
1144 |
Rifaximin delayed release 400 mg film coated tablet |
Rifaximin |
1件: D02554 D02554 💬 |
- |
- |
096 1件: 96 💬 |
1145 |
Rilutek 50 mg film-coated tablets |
- |
- |
- |
- |
002 1件: 2 💬 |
1146 |
Rilutek 50 mg, film-coated tablets |
- |
- |
- |
- |
002 1件: 2 💬 |
1147 |
Riluzolo teva - 50 mg compresse rivestite con film 90 compresse in blister al/pvc |
- |
- |
- |
- |
114 1件: 114 💬 |
1148 |
Riociguat coated tablet 0.5 mg |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
1149 |
Riociguat coated tablet 1.0 mg |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
1150 |
Riociguat coated tablet 1.5 mg |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
1151 |
Riociguat coated tablet 2.0 mg |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
1152 |
Riociguat coated tablet 2.5 m |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
1153 |
Riociguat coated tablet 2.5 mg |
Riociguat |
1件: D09572 D09572 💬 |
GUCY1A1 3件: GUCY1A1, GUCY1A2, GUCY1B1 💬 |
Circadian entrainment 11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
1154 |
Risperidone |
Risperidone |
1件: D00426 D00426 💬 |
DRD2 2件: DRD2, HTR2A 💬 |
Alcoholism 11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
008 5件: 8 , 156, 179, 187, 206 💬 |
1155 |
Rituximab combined with omalizumab |
Omalizumab |
2件: D02994 D02994, D05251 D05251 💬 |
FCER1A 2件: FCER1A, MS4A1 💬 |
Asthma 5件: Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
162 1件: 162 💬 |
1156 |
Rituximab-eu+ rituximab-pfizer x 2 courses |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
046 1件: 46 💬 |
1157 |
Rituximab-pfizer (pf-05280586) x 3 courses |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
046 1件: 46 💬 |
1158 |
Rituximab-us + rituximab-pfizer x 2 courses |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
046 1件: 46 💬 |
1159 |
Ro4964913/f07-01 (commercial) |
- |
- |
- |
- |
013 1件: 13 💬 |
1160 |
Roactemra 20 mg/ml concentrado para solución para perfusión |
- |
- |
- |
- |
046 1件: 46 💬 |
1161 |
Roactemra 20 mg/ml concentrate for solution for infusion |
- |
- |
- |
- |
046 1件: 46 💬 |
1162 |
Roactemra 20 mg/ml concentrate for solution for infusion. |
- |
- |
- |
- |
046 1件: 46 💬 |
1163 |
Roactemra 20 mg/ml, concentrado para solución para perfusión |
- |
- |
- |
- |
046 2件: 46, 271 💬 |
1164 |
Roactemra®ev product code: prd82321 |
- |
- |
- |
- |
046 1件: 46 💬 |
1165 |
Ropinirole controlled-release (requip cr) for rls |
Ropinirole |
2件: D00784 D00784, D08489 D08489 💬 |
DRD2 3件: DRD2, DRD3, DRD4 💬 |
Alcoholism 8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
1166 |
Rva576 (coversin) |
Nomacopan |
1件: D11473 D11473 💬 |
C5 1件: C5 💬 |
Complement and coagulation cascades 9件: Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus |
062 2件: 62, 109 💬 |
1167 |
S-warfarin |
Warfarin |
3件: D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
013 1件: 13 💬 |
1168 |
S95011 concentrate for solution for infusion |
- |
- |
- |
- |
053 1件: 53 💬 |
1169 |
Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group) |
Amitriptyline |
7件: D00326 D00326, D00809 D00809, D00823 D00823, D01355 D01355, D02691 D02691, D07448 D07448, D08623 D08623 💬 |
GHR 4件: GHR, OPRM1, SLC6A2, SLC6A4 💬 |
Cytokine-cytokine receptor interaction 9件: Cytokine-cytokine receptor interaction, Estrogen signaling pathway, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Serotonergic synapse, Synaptic vesicle cycle |
078 1件: 78 💬 |
1170 |
Secukinumab |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
013 7件: 13, 37, 41, 46, 160, 269, 271 💬 |
1171 |
Secukinumab (150 mg) |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
1172 |
Secukinumab (75 mg) |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
1173 |
Secukinumab (ain457) |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
046 1件: 46 💬 |
1174 |
Secukinumab (ain457) 150 mg s.c. |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
1175 |
Secukinumab 150 mg (2 injections per dose |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
269 1件: 269 💬 |
1176 |
Secukinumab 150 mg provided in 1.0 ml pre-filled syringes (pfss) for sc injection. |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
1177 |
Secukinumab 150 mg/1 ml solution for injection |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
037 2件: 37, 271 💬 |
1178 |
Secukinumab 150 milligram [cosentyx] |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
1179 |
Secukinumab 150mg |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
037 1件: 37 💬 |
1180 |
Secukinumab 300 mg, s.c. |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
041 1件: 41 💬 |
1181 |
Secukinumab 300mg |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
037 1件: 37 💬 |
1182 |
Secukinumab 75 mg/0.5 ml solution for injection |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |
1183 |
Semi continuous intra-oral administration of ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
1184 |
Serum containing avonex |
- |
- |
- |
- |
013 1件: 13 💬 |
1185 |
Sildenafil and losartan |
Losartan |
4件: D00357 D00357, D02229 D02229, D08146 D08146, D08514 D08514 💬 |
AGTR1 2件: AGTR1, PDE5A 💬 |
AGE-RAGE signaling pathway in diabetic complications 18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Purine metabolism, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
085 1件: 85 💬 |
1186 |
Simvastatin 40 mg film-coated tablets |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
013 1件: 13 💬 |
1187 |
Simvastatina sandoz 40 mg comprimidos recubiertos con película efg |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
013 1件: 13 💬 |
1188 |
Sin lv mediated ex vivo transduced autologous fibroblasts expressing codon-optimised col7a1 |
- |
- |
- |
- |
036 1件: 36 💬 |
1189 |
Sin rv-mediated col7a1 corrected autologous skin equivalent |
- |
- |
- |
- |
036 1件: 36 💬 |
1190 |
Sinemet (comparator) |
- |
- |
- |
- |
006 1件: 6 💬 |
1191 |
Sinemet 100 mg + 25 mg compresse |
- |
- |
- |
- |
006 1件: 6 💬 |
1192 |
Sinemet® controlled release (carbidopa/levodopa) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1193 |
Sinvastatina sandoz 40 mg comprimidos revestidos por película |
- |
- |
- |
- |
013 1件: 13 💬 |
1194 |
Site specific standard of care comparison |
- |
- |
- |
- |
038 2件: 38, 39 💬 |
1195 |
Sivatin 40 mg film-coated tablets |
- |
- |
- |
- |
013 1件: 13 💬 |
1196 |
Sodium chloride |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 20件: 6 , 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 78, 96, 168, 193, 227, 228, 271, 288, 299 💬 |
1197 |
Sodium chloride (7%) |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
299 1件: 299 💬 |
1198 |
Sodium chloride 0,9% |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
299 1件: 299 💬 |
1199 |
Sodium chloride 0.9% |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
014 1件: 14 💬 |
1200 |
Sodium chloride 6% |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
299 1件: 299 💬 |
1201 |
Sodium chloride 7% |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
299 1件: 299 💬 |
1202 |
Sodium chloride ph. eur. |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
299 1件: 299 💬 |
1203 |
Sodium chloride solution |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
011 3件: 11, 13, 228 💬 |
1204 |
Sodium chloride solution 0.9% |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
060 3件: 60, 288, 299 💬 |
1205 |
Sodium chloride solvent |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
228 1件: 228 💬 |
1206 |
Sodium pyruvate in 0.9% sodium chloride solution |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
299 1件: 299 💬 |
1207 |
Soliris - 300 mg concentrato per soluzione per infusione - uso endovenoso 1 flaconcino (vetro) 30 ml (10 mg/ml) |
- |
- |
- |
- |
109 1件: 109 💬 |
1208 |
Soliris 300 mg concentrado para solución para perfusión |
- |
- |
- |
- |
109 1件: 109 💬 |
1209 |
Solu-cortef |
- |
- |
- |
- |
006 3件: 6 , 81, 83 💬 |
1210 |
Solu-cortef (hydrocortisone) |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
083 1件: 83 💬 |
1211 |
Solu-cortef, powder for solution for injection, 100mg, and 'act-o-vial' |
- |
- |
- |
- |
006 1件: 6 💬 |
1212 |
Soluble prednisolone tablets |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
145 1件: 145 💬 |
1213 |
Solucion de cloruro de sodio sodium chloride solution |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
228 1件: 228 💬 |
1214 |
Solvente cloruro de sodio sodium chloride solvent |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
228 1件: 228 💬 |
1215 |
Somatropin (inn) recombinant dna orgin, escherichia coli |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
1216 |
Sorbitol |
Sorbitol |
1件: D00096 D00096 💬 |
- |
- |
006 2件: 6 , 10 💬 |
1217 |
Spironolactone and conivaptan |
Conivaptan |
3件: D00443 D00443, D01236 D01236, D07748 D07748 💬 |
AVPR1A 3件: AVPR1A, AVPR2, NR3C2 💬 |
Aldosterone-regulated sodium reabsorption 6件: Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption |
086 1件: 86 💬 |
1218 |
Spironolactone captopril carvedilol |
Captopril |
4件: D00251 D00251, D00255 D00255, D00443 D00443, D03415 D03415 💬 |
ACE 7件: ACE, ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2, NR3C2 💬 |
AMPK signaling pathway 18件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone-regulated sodium reabsorption, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
1219 |
Ss-adrenergic cocktail |
- |
- |
- |
- |
299 1件: 299 💬 |
1220 |
Stalevo (levodopa/ carbidopa/ entacapone) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1221 |
Stalevo (levodopa/carbidopa/entacapone) |
Carbidopa |
3件: D00059 D00059, D00558 D00558, D00781 D00781 💬 |
COMT 7件: COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
1222 |
Standard analgesia use [oxygen] |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
070 1件: 70 💬 |
1223 |
Standard continuous antiretroviral therapy |
- |
- |
- |
- |
265 1件: 265 💬 |
1224 |
Standard gadolinium contrast |
Gadolinium |
- |
- |
- |
013 1件: 13 💬 |
1225 |
Standard treatment with a conventional drug |
- |
- |
- |
- |
013 1件: 13 💬 |
1226 |
Stelara 130 mg concentrate for solution for infusion |
- |
- |
- |
- |
096 1件: 96 💬 |
1227 |
Sterile water |
Water |
1件: D00001 D00001 💬 |
- |
- |
078 1件: 78 💬 |
1228 |
Sterile water for injection |
Water |
1件: D00001 D00001 💬 |
- |
- |
078 1件: 78 💬 |
1229 |
Sterilised water for injections |
Water |
1件: D00001 D00001 💬 |
- |
- |
078 1件: 78 💬 |
1230 |
Subcutaneous hydrocortisone |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
081 1件: 81 💬 |
1231 |
Subcutaneous hydrocortisone 10mg |
Hydrocortisone |
1件: D00088 D00088 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
006 1件: 6 💬 |
1232 |
Subretinal injection of umbilical cord blood platelet-rich plasma (cb-prp) |
- |
- |
- |
- |
090 1件: 90 💬 |
1233 |
Sucrose |
Sucrose |
1件: D00025 D00025 💬 |
- |
- |
062 3件: 62, 96, 97 💬 |
1234 |
Sulfur colloid |
- |
- |
- |
- |
299 1件: 299 💬 |
1235 |
Sulphasalazine + hydroxychloroquine or prednisolone |
Hydroxychloroquine |
9件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301, D08050 D08050 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1236 |
Sulphsalazine, pentasa, asacol, colazide, depentum |
- |
- |
- |
- |
097 1件: 97 💬 |
1237 |
Suspension containing 250 embryonated, viable trichuris suis ova (tso)/15ml |
- |
- |
- |
- |
096 1件: 96 💬 |
1238 |
Suspension containing 250 embryonated, viable tso/15ml |
- |
- |
- |
- |
096 1件: 96 💬 |
1239 |
Suspension containing 2500 embryonated, viable trichuris suis ova (tso)/15ml |
- |
- |
- |
- |
096 1件: 96 💬 |
1240 |
Suspension containing 2500 embryonated, viable tso/15ml |
- |
- |
- |
- |
096 1件: 96 💬 |
1241 |
Suspension containing 7500 embryonated viable trichuris suis ova/15ml |
- |
- |
- |
- |
097 1件: 97 💬 |
1242 |
Suspension containing 7500 embryonated, viable trichuris suis ova (tso)/15ml |
- |
- |
- |
- |
096 1件: 96 💬 |
1243 |
Symkevi 100mg/150mg film-coated tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
1244 |
Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin) |
Aldosterone |
3件: D00150 D00150, D02014 D02014, D10528 D10528 💬 |
AGTR1 3件: AGTR1, AGTR2, NR3C2 💬 |
AGE-RAGE signaling pathway in diabetic complications 17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
222 1件: 222 💬 |
1245 |
T-peptide-crm197 conjugate |
- |
- |
- |
- |
011 1件: 11 💬 |
1246 |
Tachipirina - 1000 mg compresse 8 compresse |
- |
- |
- |
- |
014 1件: 14 💬 |
1247 |
Tachipirina - 500 mg compresse20 compresse |
- |
- |
- |
- |
013 2件: 13, 53 💬 |
1248 |
Tacrolimus combined with prednisone |
Prednisone |
3件: D00107 D00107, D00473 D00473, D08556 D08556 💬 |
NR3C1 6件: NR3C1, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
222 1件: 222 💬 |
1249 |
Tadalafil 20 mg film-coated tablets |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
1250 |
Tadalafil and ambrisentan upfront combination therapy |
Ambrisentan |
2件: D02008 D02008, D07077 D07077 💬 |
EDNRA 2件: EDNRA, PDE5A 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 2件: 51, 86 💬 |
1251 |
Tafamidis meglumine 20 mg soft gelatin capsules |
Gelatin |
4件: D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR 1件: TTR 💬 |
Thyroid hormone synthesis 1件: Thyroid hormone synthesis |
028 1件: 28 💬 |
1252 |
Tafamidis meglumine 20mg soft gelatin capsule (clinical trial image) |
Gelatin |
4件: D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR 1件: TTR 💬 |
Thyroid hormone synthesis 1件: Thyroid hormone synthesis |
028 1件: 28 💬 |
1253 |
Tafamidis meglumine 20mg soft gelatin capsule (commerical image) |
Gelatin |
4件: D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR 1件: TTR 💬 |
Thyroid hormone synthesis 1件: Thyroid hormone synthesis |
028 1件: 28 💬 |
1254 |
Tat4 gel concentration a |
- |
- |
- |
- |
265 1件: 265 💬 |
1255 |
Tat4 gel concentration b |
- |
- |
- |
- |
265 1件: 265 💬 |
1256 |
Technetium sulfur colloid |
- |
- |
- |
- |
299 1件: 299 💬 |
1257 |
Teriparatide [rdna origin] contains recombinant human parathyroid hormone (1-34) |
Parathyroid hormone |
2件: D05364 D05364, D06078 D06078 💬 |
PTH1R 2件: PTH1R, PTH2R 💬 |
Endocrine and other factor-regulated calcium reabsorption 3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
070 1件: 70 💬 |
1258 |
Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleavable linker |
Polyethylene glycol |
2件: D03370 D03370, D06078 D06078 💬 |
PTH1R 1件: PTH1R 💬 |
Endocrine and other factor-regulated calcium reabsorption 3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
235 1件: 235 💬 |
1259 |
Tetanus toxoid (tt) containing vaccine (td, tdap) |
Clostridium tetani toxoid antigen (formaldehyde inactivated) |
- |
- |
- |
013 1件: 13 💬 |
1260 |
Tetracosactide |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 4件: 83, 113, 145, 222 💬 |
1261 |
Tetracosactide acetate |
Acetate |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
083 2件: 83, 145 💬 |
1262 |
Tetracosactide hexaacetate |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
113 1件: 113 💬 |
1263 |
Tetracosactide hexacetaat |
Tetracosactide |
1件: D00284 D00284 💬 |
MC2R 1件: MC2R 💬 |
Aldosterone synthesis and secretion 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
222 1件: 222 💬 |
1264 |
The comprehensive treatment regimen of traditional chinese medicine |
- |
- |
- |
- |
222 1件: 222 💬 |
1265 |
The generic name is warfarin and many producers will be involved |
Warfarin |
3件: D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
049 1件: 49 💬 |
1266 |
The pop02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
- |
- |
- |
- |
086 1件: 86 💬 |
1267 |
The pops study is collecting pk data on children prescribed the following drugs of interest per standard of care: |
- |
- |
- |
- |
086 1件: 86 💬 |
1268 |
The yi-qi-qing-jie herbal compound |
- |
- |
- |
- |
066 1件: 66 💬 |
1269 |
Timolol alcon 0.5% collyre |
Timolol |
3件: D00378 D00378, D00603 D00603, D08600 D08600 💬 |
ADRB1 2件: ADRB1, ADRB2 💬 |
Adrenergic signaling in cardiomyocytes 10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
227 1件: 227 💬 |
1270 |
Tissue selective estrogen complex |
- |
- |
- |
- |
013 1件: 13 💬 |
1271 |
To be confirmed |
- |
- |
- |
- |
046 2件: 46, 97 💬 |
1272 |
Tobi 300mg/ 5ml solución para inhalación con nebulizador |
- |
- |
- |
- |
299 1件: 299 💬 |
1273 |
Tocilizumab and iv steroids combination |
Tocilizumab |
1件: D02596 D02596 💬 |
IL6R 1件: IL6R 💬 |
Coronavirus disease - COVID-19 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
041 1件: 41 💬 |
1274 |
Tofacitinib citrate (commercial image) |
Tofacitinib |
1件: D09970 D09970 💬 |
JAK1 4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 1件: 46 💬 |
1275 |
Tofacitinib citrate (proposed commercial formulation - debossed) |
Tofacitinib |
1件: D09970 D09970 💬 |
JAK1 4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 2件: 46, 97 💬 |
1276 |
Tofacitinib citrate (proposed commercial formulation debossed) |
Tofacitinib |
1件: D09970 D09970 💬 |
JAK1 4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 1件: 46 💬 |
1277 |
Tofacitinib citrate (proposed commercial formulation – debossed) |
Tofacitinib |
1件: D09970 D09970 💬 |
JAK1 4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 2件: 46, 97 💬 |
1278 |
Tofacitinib citrate (proposed commercial formulation- debossed) |
Tofacitinib |
1件: D09970 D09970 💬 |
JAK1 4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 1件: 46 💬 |
1279 |
Tofacitinib citrate (proposed commercialformulation - debossed) |
Tofacitinib |
1件: D09970 D09970 💬 |
JAK1 4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
097 1件: 97 💬 |
1280 |
Topical compound tripterygium |
Tripterygium wilfordii whole |
- |
- |
- |
046 1件: 46 💬 |
1281 |
Tp05 coating a |
- |
- |
- |
- |
097 1件: 97 💬 |
1282 |
Tp05 coating b |
- |
- |
- |
- |
097 1件: 97 💬 |
1283 |
Tp05 coating d |
- |
- |
- |
- |
097 1件: 97 💬 |
1284 |
Tp05 coating e |
- |
- |
- |
- |
097 1件: 97 💬 |
1285 |
Tp05 coating h |
- |
- |
- |
- |
097 1件: 97 💬 |
1286 |
Tracleer 62,5 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
1287 |
Traditional chinese medicinal mixture (composed of roucongrong and adjuvant) |
- |
- |
- |
- |
006 1件: 6 💬 |
1288 |
Tralokinumab cohort 1 |
Tralokinumab |
1件: D09979 D09979 💬 |
IL13 1件: IL13 💬 |
Asthma 8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
085 1件: 85 💬 |
1289 |
Tralokinumab cohort 2 |
Tralokinumab |
1件: D09979 D09979 💬 |
IL13 1件: IL13 💬 |
Asthma 8件: Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation |
085 1件: 85 💬 |
1290 |
Tramadol |
Tramadol |
2件: D01355 D01355, D08623 D08623 💬 |
OPRM1 1件: OPRM1 💬 |
Estrogen signaling pathway 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 5件: 46, 70, 78, 226, 271 💬 |
1291 |
Tramadol /acetaminophen |
Acetaminophen |
3件: D00217 D00217, D01355 D01355, D08623 D08623 💬 |
OPRM1 3件: OPRM1, PTGS1, PTGS2 💬 |
Alzheimer disease 26件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Estrogen signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
271 1件: 271 💬 |
1292 |
Tramadol hydrochloride + acetaminophen |
Acetaminophen |
3件: D00217 D00217, D01355 D01355, D08623 D08623 💬 |
OPRM1 3件: OPRM1, PTGS1, PTGS2 💬 |
Alzheimer disease 26件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Estrogen signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, Morphine addiction, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 1件: 46 💬 |
1293 |
Tramadol with ropivacaine |
Ropivacaine |
4件: D01355 D01355, D04048 D04048, D08490 D08490, D08623 D08623 💬 |
OPRM1 6件: OPRM1, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 6件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction |
070 1件: 70 💬 |
1294 |
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a col17a1-encoding retroviral vector |
- |
- |
- |
- |
036 1件: 36 💬 |
1295 |
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a col7a1-encoding retroviral vector |
- |
- |
- |
- |
036 1件: 36 💬 |
1296 |
Transduced keratinocytes suspension, containing epidermal stem cells genetically corrected with a col7a1-encoding retroviral vector, obtained from secondary culture of ex vivo expanded autologous human keratinocytes. |
- |
- |
- |
- |
036 1件: 36 💬 |
1297 |
Transplant conditioning with mobilization and alemtuzumab |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
065 1件: 65 💬 |
1298 |
Transplant conditioning with mobilization only |
- |
- |
- |
- |
065 1件: 65 💬 |
1299 |
Treatment with topical superpotent corticosteroid therapy |
- |
- |
- |
- |
162 1件: 162 💬 |
1300 |
Trexan+salazopyrin+oxiklorin+prednisolone |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
1301 |
Trexan+salazopyrin+oxiklorin+prednisolone + infliximab |
Infliximab |
9件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02598 D02598, D03301 D03301 💬 |
NR3C1 2件: NR3C1, TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 66件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
1302 |
Triple combination therapy |
- |
- |
- |
- |
299 1件: 299 💬 |
1303 |
Triptolide-containing formulation |
Triptolide |
- |
- |
- |
067 1件: 67 💬 |
1304 |
Triterpene dry extract from birch cork |
- |
- |
- |
- |
036 1件: 36 💬 |
1305 |
Tysabri 300 mg concentrado para solución para perfusión |
- |
- |
- |
- |
013 1件: 13 💬 |
1306 |
Tysabri 300 mg concentrate for solution for infusion |
- |
- |
- |
- |
013 1件: 13 💬 |
1307 |
Ultrasound microbubble contrast agent |
- |
- |
- |
- |
096 1件: 96 💬 |
1308 |
Umbilical cord blood |
- |
- |
- |
- |
060 1件: 60 💬 |
1309 |
Umbilical cord blood after myeloablative conditioning |
- |
- |
- |
- |
060 1件: 60 💬 |
1310 |
Umbilical cord blood after reduced-intensity conditioning |
- |
- |
- |
- |
060 1件: 60 💬 |
1311 |
Umbilical cord blood transplantation |
- |
- |
- |
- |
060 1件: 60 💬 |
1312 |
Umbilical cord blood unit |
- |
- |
- |
- |
333 1件: 333 💬 |
1313 |
Umbilical cord derived mesenchymal stem cell (uc -msc) transplantation |
- |
- |
- |
- |
093 2件: 93, 296 💬 |
1314 |
Umbilical cord derived mesenchymal stem cells |
- |
- |
- |
- |
013 1件: 13 💬 |
1315 |
Umbilical cord mesenchymal stem cell |
- |
- |
- |
- |
113 1件: 113 💬 |
1316 |
Umbilical cord mesenchymal stem cell (uc-msc) |
- |
- |
- |
- |
090 1件: 90 💬 |
1317 |
Umbilical cord mesenchymal stem cells |
- |
- |
- |
- |
013 5件: 13, 46, 57, 97, 113 💬 |
1318 |
Umbilical cord-derived mesenchymal stem cells (uc-mscs) |
Human Umbilical Cord Mesenchymal Stem Cells |
- |
- |
- |
046 1件: 46 💬 |
1319 |
Unrelated cord blood |
- |
- |
- |
- |
065 1件: 65 💬 |
1320 |
Unrelated umbilical cord blood transplant |
- |
- |
- |
- |
019 1件: 19 💬 |
1321 |
Upadacitinib - direct compression-yellow |
Upadacitinib |
1件: D10994 D10994 💬 |
JAK1 1件: JAK1 💬 |
Coronavirus disease - COVID-19 27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
097 1件: 97 💬 |
1322 |
Upadacitinib -direct compression-yellow |
Upadacitinib |
1件: D10994 D10994 💬 |
JAK1 1件: JAK1 💬 |
Coronavirus disease - COVID-19 27件: Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
097 1件: 97 💬 |
1323 |
Urbason 40 mg comprimidos |
- |
- |
- |
- |
013 1件: 13 💬 |
1324 |
Ursodeoxycholic acid combination of immunosuppressive agents |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 2件: 93, 95 💬 |
1325 |
Ursodeoxycholic acid combined with total glucosides of paeony |
Ursodeoxycholic acid |
1件: D00734 D00734 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
093 1件: 93 💬 |
1326 |
Ursofalk® 500 mg film-coated tablets |
- |
- |
- |
- |
093 1件: 93 💬 |
1327 |
Us tap bupivacaine/epinephrine |
Bupivacaine |
5件: D00095 D00095, D00996 D00996, D01450 D01450, D02149 D02149, D07552 D07552 💬 |
ADRA1A 14件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
AMPK signaling pathway 15件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
096 1件: 96 💬 |
1328 |
V1512 and entacapone |
Entacapone |
1件: D00781 D00781 💬 |
COMT 1件: COMT 💬 |
Dopaminergic synapse 4件: Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism |
006 1件: 6 💬 |
1329 |
Valproid acid plus corticosteroids |
- |
- |
- |
- |
026 1件: 26 💬 |
1330 |
Vastarel 20mg film coated tablets |
- |
- |
- |
- |
058 1件: 58 💬 |
1331 |
Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana |
- |
- |
- |
- |
019 1件: 19 💬 |
1332 |
Vehice control |
- |
- |
- |
- |
096 1件: 96 💬 |
1333 |
Vehicle control |
- |
- |
- |
- |
053 1件: 53 💬 |
1334 |
Verapamil |
Verapamil |
2件: D00619 D00619, D02356 D02356 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
096 3件: 96, 140, 167 💬 |
1335 |
Verapamil sr |
Verapamil |
2件: D00619 D00619, D02356 D02356 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
167 1件: 167 💬 |
1336 |
Vett lentiviral con gene abca4 |
- |
- |
- |
- |
301 1件: 301 💬 |
1337 |
Viokase 16 (pancrelipase) + nexium |
Pancrelipase |
1件: D05349 D05349 💬 |
- |
- |
298 1件: 298 💬 |
1338 |
Volibris 10 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
1339 |
Volibris 5 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
1340 |
Von willebrand factor and coagulation factor viii in combination |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
1341 |
Von willebrand factor ristocetin cofactor |
Von Willebrand Factor Human |
- |
- |
- |
288 1件: 288 💬 |
1342 |
Vwd factor viii concentrate |
Beroctocog alfa |
- |
- |
- |
288 1件: 288 💬 |
1343 |
Vwf-containing products |
- |
- |
- |
- |
288 1件: 288 💬 |
1344 |
Vx-661 plus ivacaftor combination |
Ivacaftor |
1件: D09916 D09916 💬 |
CFTR 1件: CFTR 💬 |
ABC transporters 8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway |
299 1件: 299 💬 |
1345 |
Warfarin |
Warfarin |
3件: D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
006 11件: 6 , 8 , 13, 19, 46, 49, 66, 85, 88, 96, 97 💬 |
1346 |
Warfarin 10 mg |
Warfarin |
3件: D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
096 2件: 96, 97 💬 |
1347 |
Warfarin sodium |
Warfarin |
3件: D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
049 1件: 49 💬 |
1348 |
Warfarin+ vitamin k |
Phylloquinone |
4件: D00148 D00148, D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
046 1件: 46 💬 |
1349 |
Water |
Water |
1件: D00001 D00001 💬 |
- |
- |
002 22件: 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
1350 |
Water for injection |
Water |
1件: D00001 D00001 💬 |
- |
- |
035 1件: 35 💬 |
1351 |
Water for injections |
Water |
1件: D00001 D00001 💬 |
- |
- |
299 1件: 299 💬 |
1352 |
Water for injections, ep |
Water |
1件: D00001 D00001 💬 |
- |
- |
299 1件: 299 💬 |
1353 |
White chocolate (0% cocoa) |
Cocoa |
- |
- |
- |
006 1件: 6 💬 |
1354 |
Xeljanz 5 mg film-coated tablets |
- |
- |
- |
- |
046 2件: 46, 97 💬 |
1355 |
Xeljanz 5mg film-coated tablets |
- |
- |
- |
- |
097 1件: 97 💬 |
1356 |
Xenon contrast agent |
Xenon |
2件: D01901 D01901, D06339 D06339 💬 |
- |
- |
022 1件: 22 💬 |
1357 |
Xyzal - 20 compresse ri |
- |
- |
- |
- |
053 1件: 53 💬 |
1358 |
Yondelis 0,25 mg polvo para concentrado para solución para perfusión |
- |
- |
- |
- |
159 1件: 159 💬 |
1359 |
Yondelis 0.25 mg powder for concentrate for solution for infusion. |
- |
- |
- |
- |
159 1件: 159 💬 |
1360 |
Yondelis 1 mg polvo para concentrado para solución para perfusión |
- |
- |
- |
- |
159 1件: 159 💬 |
1361 |
Yondelis 1 mg powder for concentrate for solution for infusion. |
- |
- |
- |
- |
159 1件: 159 💬 |
1362 |
Z102 (prednisolone and dipyridamole). |
Dipyridamole |
9件: D00302 D00302, D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 3件: NR3C1, PDE4A, PDE5A 💬 |
Metabolic pathways 7件: Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
046 1件: 46 💬 |
1363 |
Zinc and copper |
Copper |
- |
- |
- |
002 1件: 2 💬 |
1364 |
Zuglimet - 500 mg compresse rivestite con film 30 compresse in blister pvc/al |
- |
- |
- |
- |
067 1件: 67 💬 |